The Record header image

Subscribe  |  The Record Archive  |  Contacts  |  bcbsm.com

November 2023

All Providers

Blue Cross and BCN receive 4-Star ratings from CMS

The Centers for Medicare & Medicaid Services recently announced its 2024 Medicare Star Ratings. Both our BCN Advantage℠ HMO plan and our Medicare Plus Blue℠ PPO plan captured 4-Star ratings, making our plans once again among the highest rated Medicare Advantage plans in the country.

Star Ratings are CMS’ measure of how well health plans serve MA members. They’re designed to evaluate how well plans that contract with Medicare perform, and to help consumers select a Medicare Advantage plan that works best for them.

“Star Ratings are vital to our mission to serve our Medicare Advantage members,” said Daniel J. Loepp, Blue Cross Blue Shield of Michigan president and CEO. “We value the provider community’s partnership when it comes to delivering exceptional, high-quality care — a key factor that drove our strong ratings.”

Why value-based care matters when it comes to Star Ratings

The measures that the Star Ratings system considers overlap with value-based care model outcomes. Health care providers who are in value-based care arrangements outperform their peers in key measures related to quality and cost, including better performance in rates of breast cancer and colorectal screenings, and diabetic control measures.

“When we look at these performance measures and how our Star Ratings are calculated, it’s clear that value-based care is a winning path forward for everyone,” said Dr. James Grant, senior vice president and chief medical officer for Blue Cross. “We couldn’t have achieved these Star Ratings without our physician partners, and we look forward to the future as we continue to meaningfully engage everyone in value-based arrangements that will benefit our members.”

The goal for the 2025 rating year is to maintain or exceed 4-Star ratings for the PPO and HMO.

A deeper dive into the ratings

Medicare considers five categories when assigning Star Ratings:

  • Maintaining health for members, including benefits such as cancer screenings and vaccines
  • Managing chronic conditions, such as diabetes and blood pressure
  • Customer service, including how responsive the plan is, as well as the quality of care that people with the plan receive
  • Member complaint reports, which include problems in getting services and decisions on appeals
  • Member experience with their plan, quality of care received and access to care

Blue Cross’ 4-Star ratings for 2024 reflect sustained performance in several key areas, including HEDIS® measures** and CAHPS® surveys.*** The Consumer Assessment of Healthcare Providers and Systems surveys, developed by the Agency for Healthcare Research and Quality, evaluate a member’s experience with their plan, quality of care received and access to care.

**HEDIS®, which stands for Healthcare Effectiveness and Information Set, is a registered trademark of the National Committee for Quality Assurance.

***CAHPS®, which stands for Consumer Assessment of Healthcare Providers and Systems, is a registered trademark of the Agency for Healthcare Quality and Research.


Your patients can order free, at-home COVID-19 tests

Due to an increase in demand for COVID-19 testing, the federal government is restarting a program for each U.S. household to order four free COVID-19 rapid tests for mail delivery. These tests can be ordered through COVIDtests.gov.**

Share this information with your patients who may benefit from having at-home COVID-19 rapid tests.

Note: COVIDtests.gov** also provides the following information:

**Blue Cross Blue Shield of Michigan doesn’t own or control this website.


Where to view provider portal change and status updates

Are you curious about what’s new with our provider portal, Availity® Essentials?

We’re always working to improve your experience in our provider portal. Here are a couple of examples:

  • We updated member search results to include the type of services that are covered (medical, behavioral health, pharmacy, hearing or vision) and to specify the time frame during which the member’s coverage is in effect. In addition, search results now include group numbers and suffixes for members with Blue Cross Blue Shield of Michigan plans and group numbers for members with Blue Care Network plans.
  • We updated the Coordination of Benefits section to display the payer as Blue Cross Blue Shield of Michigan, Medicare Plus Blue℠ or Blue Care Network, rather than displaying the more generic BCBS Michigan and Blue Care Network.

To stay up to date with the latest provider portal news, you can access the Provider Portal Change and Status Updates document, which includes information about important updates, known defects and workarounds. We update this document monthly or more often, as needed.

To view this document:

  1. Log in to our provider portal (availity.com).**
  2. Click on Payer Spaces on the menu bar and then click on the BCBSM and BCN logo.
  3. Click on the News and Announcements tab.
  4. Click on the Provider Portal Change and Status Updates (PDF) link.

Availity is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to offer provider portal and electronic data interchange services.

**Blue Cross Blue Shield of Michigan doesn’t own or control this website.


New location of pharmacy services information for providers on our public website

We’ve relocated our pharmacy services information for providers on our public website. This site contains information on medical and pharmacy benefit drug lists for both Blue Cross Blue Shield of Michigan and Blue Care Network, Medicare and pharmacy forms and documents, prior authorization request information and other resources. Here’s how to find it:

  1. Go to bcbsm.com/providers.
  2. Click on the Resources tab.
  3. Scroll down to the Pharmacy information section and click on Access pharmacy resources to open the Pharmacy Resources for Providers webpage.

HCPCS 3rd-quarter update: New and deleted codes

The Centers for Medicare & Medicaid Services has added several new codes as part of its quarterly Health Care Procedure Coding System updates. The codes, effective dates and Blue Cross Blue Shield of Michigan’s coverage decisions are below.

Radiopharmaceuticals

Radiology

Code

Change

Coverage comments

Effective date

A9573

Added

Covered

Oct. 1, 2023

A9603

Added

Covered

Oct. 1, 2023

A9697

Added

Covered

Oct. 1, 2023

Injections/Outpatient PPS

Code

Change

Coverage comments

Effective date

C9151

Delete

Deleted Sept. 30, 2023

Sept. 30, 2023

C9152

Added

Covered for facility only

Oct. 1, 2023

C9153

Added

Covered for facility only

Oct. 1, 2023

C9154

Added

Covered for facility only

Oct. 1, 2023

C9155

Added

Requires manual review

Oct. 1, 2023

C9156

Added

Covered for facility only

Oct. 1, 2023

C9157

Added

Requires manual review

Oct. 1, 2023

C9158

Added

Covered for facility Only

Oct. 1, 2023

Injections

Code

Change

Coverage comments

Effective date

J0349

Added

Covered

Oct. 1, 2023

J0800

Delete

Deleted Sept. 30, 2023

Sept. 30, 2023

J0801

Added

Requires manual review

Oct. 1, 2023

J0802

Added

Requires manual review

Oct. 1, 2023

J0874

Added

Covered

Oct. 1, 2023

J0889

Added

Not covered

Oct. 1, 2023

J2359

Added

Covered

Oct. 1, 2023

J2781

Added

Requires manual review

Oct. 1, 2023

J7214

Added

Covered

Oct. 1, 2023

J7519

Added

Covered

Oct. 1, 2023

J9051

Added

Covered

Oct. 1, 2023

J9064

Added

Covered

Oct. 1, 2023

J9345

Added

Covered

Oct. 1, 2023

Surgery/Drugs Administered Other Than Oral Method

Code

Change

Coverage comments

Effective date

J7353

Added

Covered

Oct. 1, 2023

Behavioral Health

Code

Change

Coverage comments

Effective date

H2040

Added

Covered

Oct. 1, 2023

H2041

Added

Covered

Oct. 1, 2023

Durable Medical Equipment

Code

Change

Coverage comments

Effective date

A9156

Added

Not covered

Oct. 1, 2023

A9268

Added

Not covered

Oct. 1, 2023

A9269

Added

Not covered

Oct. 1, 2023

B4148

Added

Covered

Oct. 1, 2023

K1036

Added

Not covered

Oct. 1, 2023

Prosthetic and Orthotic

Code

Change

Coverage comments

Effective date

L1681

Added

Covered

Oct. 1, 2023

L5991

Added

Covered

Oct. 1, 2023

V2526

Added

Covered

Oct. 1, 2023

Surgery/Skin Substitutes

Code

Change

Coverage comments

Effective date

A2022

Added

Covered

Oct. 1, 2023

A2023

Added

Covered

Oct. 1, 2023

Q4285

Added

Not covered

Oct. 1, 2023

Q4286

Added

Not covered

Oct. 1, 2023

Other Medical Services

Code

Change

Coverage comments

Effective date

A9292

Added

Experimental

Oct. 1, 2023

None of the information included in this article is intended to be legal advice and, as such, it remains the provider’s responsibility to ensure that all coding and documentation are done in accordance with all applicable state and federal laws and regulations.


HCPCS replacement codes established, effective Oct. 1

J0801 replaces J0800 when billing for Acthar Gel (corticotropin)

Effective Oct. 1, 2023, the Centers for Medicare & Medicaid Services has established a new procedure code for specialty medical drug Acthar Gel (corticotropin).                     

All services through Sept. 30, 2023, should be reported with code J0800. All services performed on and after Oct. 1, 2023, must be reported with J0801.

Prior authorization is required through the Medical Benefit Drug Program for J0801 for all groups unless they have opted out of the program.

For groups that have opted out of the prior authorization program, this service requires manual review for individual consideration.

J0802 replaces C9399, J3490, J3590 and J9999 when billing for Purified Cortrophin Gel (corticotropin)

Effective Oct. 1, 2023, CMS has established a permanent procedure code for specialty medical drug Purified Cortrophin Gel (corticotropin).

All services through Sept. 30, 2023, should be reported with code C9399, J3490, J3590 and J9999. All services performed on and after Oct. 1, 2023, must be reported with J0802.

Prior authorization is required through the Medical Benefit Drug Program for J0802 for all groups unless they have opted out of the program

For groups that have opted out of the prior authorization program, this service requires manual review for individual consideration.

J2781 replaces C9399, J3490, J3590 and J9999 when billing for Syfovre (pegcetacoplan)

Effective Oct. 1, 2023, CMS has established a permanent procedure code for specialty medical drug Syfovre (pegcetacoplan).

All services through Sept. 30, 2023, should be reported with code C9399, J3490, J3590 and J9999. All services performed on and after Oct. 1, 2023, must be reported with J2781.

Prior authorization is required through the Medical Benefit Drug Program for J2781 for all groups unless they have opted out of the program.

For groups that have opted out of the prior authorization program, this service requires manual review for individual consideration.

None of the information included in this article is intended to be legal advice and, as such, it remains the provider’s responsibility to ensure that all coding and documentation are done in accordance with all applicable state and federal laws and regulations.


Billing chart: Blue Cross highlights medical, benefit policy changes

You’ll find the latest information about procedure codes and Blue Cross Blue Shield of Michigan billing guidelines in the following chart.

This billing chart is organized numerically by procedure code. Newly approved procedures will appear under the New Payable Procedures heading. Procedures for which we have changed a billing guideline or added a new payable group will appear under Updates to Payable Procedures. Procedures for which we are clarifying our guidelines will appear under Policy Clarifications. New procedures that are not covered will appear under Experimental Procedures.

We'll publish information about new Blue Cross groups or changes to group benefits under the Group Benefit Changes heading.

For more detailed descriptions of the Blue Cross' policies for these procedures, check under the Commercial Policy tab in Benefit Explainer on Availity®. To access this online information:

    1. Log in to availity.com.
    2 .Click on Payer Spaces on the Availity menu bar.
    3. Click on the BCBSM and BCN logo.
    4. Click on Benefit Explainer on the Applications tab.
    5. Click on the Commercial Policy tab.
    6. Click on Topic.
    7. Under Topic Criteria, click on the circle for Unique Identifier and click the drop-down arrow next to Choose Identifier Type, then click on HCPCS Code.
    8. Enter the procedure code.
    9. Click on Finish.
    10. Click on Search.
Code* BCBSM changes to:
Basic Benefit and Medical Policy, Group
Variations Payment Policy, Guidelines
UPDATES TO PAYABLE PROCEDURES

81450, 81455 

Basic benefit and medical policy

Updated medical policies

Updates have been made to the covered conditions for a panel test that evaluates hematolymphoid neoplasms or disorders, and another test that evaluates both hematolymphoid and solid organ tumors. These changes were made to align the payable diagnoses with various criteria outlined in several policies. The changes were effective March 1, 2023.

The following medical policies can be viewed on the Medical Policy Router or Benefit Explainer:

  • Genetic Testing – Next Generation Sequencing of Multiple Genes (Panel) for Malignant Conditions
  • Genetic Testing – JAK2, MPL and CALR Testing for Myeloproliferative Neoplasms
  • Genetic Testing for FMR1 and FMR2 variants (Including Fragile X and Fragile XE Syndromes)
  • Genetic Testing for FLT3, NPM1, CEBPA, IDH1 and IDH2 Variants in Acute Myeloid Leukemia
  • Genetic Testing – BCR-ABL1 Testing in Chronic Myelogenous Leukemia and Acute Lymphoblastic Leukemia

Payable diagnoses:

D61.818, D72.824, D75.81 and E88.09, plus the range of malignant conditions

J9035
Q5107
Q5118
Q5126

Basic benefit and medical policy

Off-label use of Avastin (bevacizumab)

Blue Cross Blue Shield of Michigan has approved payment for the off-label use of Avastin (bevacizumab). The listed procedure codes are payable for off-label use to treat endometrial cancer.

URMBT groups are excluded from this change.

POLICY CLARIFICATIONS

20930, 22533, 22558

Basic benefit and medical policy

Bone morphogenetic protein

The safety and effectiveness of the use of recombinant human bone morphogenetic protein-2 (Infuse™) have been established in skeletally mature patients, effective Sept. 1, 2023.

Inclusions:

The use of recombinant human bone morphogenetic protein-2 (Infuse™) is indicated in skeletally mature patients when used as described per FDA approval (one of the following criteria must apply):

  1. For spinal indications when used with the appropriate FDA-approved cage and all the following criteria are met:
    • Surgery is planned for one level from L2-S1 for the treatment of degenerative disc disease through an anterior, oblique or direct lateral approach.
    • There’s a high risk for failure of fusion (prior failed spinal fusion, recent history of smoking, presence of diabetes or renal disease, alcoholism, long-term steroid use or osteoporosis).
    • Autologous bone or marrow isn’t feasible** or not expected to promote fusion.
  2. For use in tibia trauma indications when the following criterion is met:
    • For the treatment of acute, open fracture of the tibial shaft when the use of autograft is not feasible.**

**Use of autologous (iliac crest bone) graft may be considered not feasible due to situations that may include, but aren’t limited to, prior harvesting of iliac crest bone graft or need for a greater quantity of iliac crest bone graft than available (for example, for multilevel fusion).

Exclusions:

The use of recombinant human bone morphogenetic protein-2 is considered experimental for all other indications not listed above including, but not limited to, spinal fusion when the use of autograft is feasible and craniomaxillofacial surgery, or when any of the following are present:

  1. Planned posterior approach fusion
  2. Cervical or thoracic indications
  3. Known sensitivity to implant material or bovine type I collagen, or with an allergy to titanium (including alloys) or polyetheretherketone
  4. Use near the site of extant or resected tumor, or for patients with active malignancy or receiving treatment for cancer
  5. Infection at the planned operative site
  6. Pediatric patients younger than 18, or skeletal immaturity
  7. Female patients who are pregnant or those planning to become pregnant within one year of placement

89253

Basic benefit and medical policy

*89253 removed from Physician Office Laboratory List

Procedure code *89253 was removed from the Physician Office Laboratory List. This procedure can no longer be performed in a physician’s office.

C9399
J3490
J3590
J9999

Basic benefit and medical policy

Columvi (glofitamab-gxbm)

Effective June 15, 2023, Columvi (glofitamab-gxbm) is considered established when criteria are met. 

Columvi (glofitamab-gxbm) is a bispecific CD20-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, or DLBCL, NOS, or large B-cell lymphoma, known as LBCL, arising from follicular lymphoma, after two or more lines of systemic therapy.

This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Dosage and administration:

  • Pretreat with a single 1,000 mg dose of obinutuzumab intravenously seven days before initiation of Columvi (glofitamab-gxbm); Cycle 1, Day 1.
  • Administer premedications as recommended.
  • Administer only as an intravenous infusion.
  • Recommended dosage:
  • Treatment Cycle 1
    Day 1 – Obinutuzumab 1,000 mg
    Day 8 – Step-up dose 1 2.5 mg
    Day 15 – Step-up dose 2 10 mg

    Treatment Cycle 2-12
    Day 1 – 30 mg

    Cycle = 21 days  

  • Administer in a facility equipped to monitor and manage CRS.
  • Patients should be hospitalized for the 2.5 mg step-up dose and for subsequent infusions as recommended.

Dosage forms and strengths:

Injection:

  • 2.5 mg/2.5 mL (1 mg/mL) in a single-dose vial.
  • 10 mg/10 mL (1 mg/mL) in a single-dose vial.

Columvi (glofitamab-gxbm) isn’t covered for URMBT.

J0172
J1427
J1428

Basic benefit and medical policy

Aduhelm (aducanumab-avwa), Viltepso (viltolarsen) and Exondys 51 (eteplirsen)

The medical drugs Aduhelm (aducanumab-avwa), Viltepso (viltolarsen) and Exondys 51 (eteplirsen) are considered experimental. This change is effective Oct. 1, 2023.

J0565

Basic benefit and medical policy

Zinplava (bezlotoxumab)

Effective May 26, 2023, Zinplava (bezlotoxumab) is covered for the following FDA-approved indication:

Zinplava (bezlotoxumab) is a human monoclonal antibody that binds to Clostridioides difficile toxin B, used to reduce recurrence of clostridioides difficile infection, or CDI, in adults and pediatric patients 1 year and older who are receiving antibacterial drug treatment for CDI and are at a high risk for CDI recurrence.

J3490
J3590

Basic benefit and medical policy

Lantidra (donislecel-jujn)

Lantidra (donislecel-jujn) is considered established, effective June 29, 2023. 

Lantidra is an allogeneic pancreatic islet cellular therapy indicated for the treatment of adults with Type 1 diabetes who are unable to approach target HbA1c because of current repeated episodes of severe hypoglycemia despite intensive diabetes management and education. Use in conjunction with concomitant immunosuppression.

Dosage and administration:

For infusion into the hepatic portal vein only

  • Don’t irradiate.
  • Don’t use leukodepleting filters.
  • Don’t use if product time exceeds six hours post-product release or if temperature isn’t maintained between 15 and 25 degrees Celsius.
  • The recommended minimum dose is 5,000 equivalent islet number, or EIN, per kg patient body weight for initial infusion (transplant) and 4,500 EIN/kg for subsequent infusions (same recipient).
  • Administer cells through the hepatic portal vein. The estimated tissue volume shouldn’t exceed 10 cc per transplant infusion.

Dosage forms and strengths:

The dosage form is a cellular suspension. Dosage strength depends on the total number of islets packaged for infusion, which is reported on the container label and associated documents.

This drug isn’t a benefit for URMBT.

J3490
J3590

Basic benefit and medical policy

Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc)

Effective June 20, 2023, Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) is covered for the following FDA-approved indications:

Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) is a combination of efgartigimod alfa, a neonatal Fc receptor blocker, and hyaluronidase, an endoglycosidase, indicated for the treatment of generalized myasthenia gravis, or gMG, in adult patients who are anti-acetylcholine receptor, or AChR, antibody positive.

Dosage and administration:

  • Evaluate the need to administer age-appropriate vaccines according to immunization guidelines before initiation of a new treatment cycle with Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc).
  • Administer by a health care professional only.
  • For subcutaneous use with a winged infusion set.
  • The recommended dose is 1,008 mg / 11,200 units (1,008 mg efgartigimod alfa and 11,200 units hyaluronidase) administered subcutaneously over approximately 30 to 90 seconds in cycles of once-weekly injections for four weeks.
  • Administer subsequent treatment cycles based on clinical evaluation; the safety of initiating subsequent cycles sooner than 50 days from the start of the previous treatment cycle hasn’t been established.

Dosage forms and strengths:

Injection: 1,008 mg efgartigimod alfa and 11,200 units hyaluronidase per 5.6 mL (180 mg/2,000 units per mL) in a single-dose vial

Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) isn’t a benefit for URMBT.

J9271

Basic benefit and medical policy

Keytruda (pembrolizumab)

Effective April 3, 2023, Keytruda (pembrolizumab) is no longer payable for the following indication and usage.

The following statement has been removed from the Urothelial Carcinoma Indication:

  • Patients whose tumors express PD-L1 (Combined Positive Score ≥10) as determined by an FDA-approved test, or in patients who aren’t eligible for any platinum-containing chemotherapy regardless of PD-L1 status.

The following limitation of use statement has been removed from the Microsatellite Instability-High Cancer or Mismatch Repair Deficient Cancer Indication:

  • The safety and effectiveness of Keytruda in pediatric patients with MSI-H central nervous system cancers haven’t been established.

J9309

Basic benefit and medical policy

Polivy (polatuzumab vedotin-piiq)

Effective April 19, 2023, Polivy® (polatuzumab vedotin-piiq) is indicated for the following new FDA-approved indication:

In combination with a rituximab product, cyclophosphamide, doxorubicin and prednisone, or R-CHP, for the treatment of adult patients who have previously untreated diffuse large B-cell lymphoma, not otherwise specified, or high-grade B-cell lymphoma and who have an International Prognostic Index score of 2 or greater.

Condition Code 45

Basic benefit and medical policy

Revised nomenclature of Condition Code 45

The National Uniform Billing Committee revised the nomenclature/description of Condition Code 45 to Gender Incongruence, effective July 1, 2023.

Value Code 42

Basic benefit and medical policy

Revised nomenclature of Value Code 42

The National Uniform Billing Committee revised the nomenclature of Value Code 42 to VA or PACE retroactively for an effective date of July 1, 2023.

EXPERIMENTAL PROCEDURES

98978, A9291

Basic benefit and medical policy

Digital health therapies for substance use

Digital health therapies for individuals with substance use disorders are considered experimental.

Procedure code *98978 was originally loaded as payable but was considered experimental as of Aug. 1, 2023.

Inclusionary guidelines and exclusionary guidelines:

Not applicable

GROUP BENEFIT CHANGES

Lacks Enterprises, Inc.

Lacks Enterprises, Inc., group number 000071855, is returning to Blue Cross Blue Shield of Michigan, effective Jan. 1, 2024. 

Group number: 000071855
Alpha prefix: A4F
Platform: NASCO

Plans offered:
HDHP-PPO Standard Blue Cross PPO Network
Medical
Virtual Care by Teladoc Health™ (formerly Blue Cross Online Visits℠)
Advocate (formerly known as Navigator)
Pharmacy is carved out to Magellan.

Lacks offers near-site clinics managed by Trinity Health

Teladoc Health is an independent company that provides virtual care solutions for Blue Cross Blue Shield of Michigan.

None of the information included in this billing chart is intended to be legal advice and, as such, it remains the provider’s responsibility to ensure that all coding and documentation are done in accordance with all applicable state and federal laws and regulations.

Professional

2 new Medicare Plus Blue plans can help members save in 2024

This fall, during open enrollment for 2024, Blue Cross Blue Shield of Michigan is offering two new Medicare Plus Blue℠ plans for individual plan members. In addition to the Essential, Vitality, Signature or Assure plans, members can now choose:

  • Medicare Plus Blue℠ Part B Credit
  • Medicare Plus Blue℠ PPO + Meijer

Here are key details about the plans and benefits, which will take effect Jan. 1, 2024:

Medicare Plus Blue Part B Credit

Our Medicare Plus Blue Part B Credit plan reduces the Part B premium that all Medicare beneficiaries have to pay each month. Members who enroll in this plan will:

  • Receive a $100 credit in their monthly Social Security checks
  • Still have the same benefits as the other individual Medicare Plus Blue plans

Members aren’t eligible for the Part B Credit plan if they receive premium assistance from Medicaid or another source.

Medicare Plus Blue PPO + Meijer                                                                       

Blue Cross is working with retail supercenter Meijer to offer the new Medicare Plus Blue PPO + Meijer plan with a $0 premium. This plan offers an affordable, convenient option for Medicare Plus Blue members who shop at Meijer.

The plan adds Meijer to the list of plan-approved retailers that members can choose from to use their over-the-counter allowance benefit.

Members who enroll in the Medicare Plus Blue PPO + Meijer plan can use their $660 annual in-store allowance in Meijer stores to purchase:

  • Approved nonprescription, over-the-counter drugs and wellness-related items, such as vitamins and bandages
  • Available healthy foods for qualifying members who have a chronic condition

Both the Medicare Plus Blue PPO Part B Credit and the Medicare Plus Blue PPO + Meijer plans offer the same large array of preventive and supplemental benefits our current members have to help keep them healthy. This includes:

  • The over-the-counter quarterly allowance
  • Support for caregivers of enrollees
  • Comprehensive dental and vision care
  • Transportation to an enhanced wellness visit
  • Fitness through SilverSneakers®

Note: You’ll want to check your patient’s eligibility and benefits to ensure they have access to the SilverSneakers fitness program.

SilverSneakers is a registered trademark of Tivity Health, Inc. © 2023 Tivity Health, Inc. All rights reserved.


New enhanced benefits will be available to Medicare Advantage members in 2024

Medicare Plus Blue℠ and BCN Advantage℠ are adding three new enhanced benefits to their comprehensive Medicare Advantage plans for the 2024 plan year. Beginning Jan. 1, 2024, members can capitalize on the following new benefits:

  • Ambulance services without transport
  • Enhanced annual wellness visit
  • Mobile crisis and crisis stabilization for behavioral health (available for members who reside in select counties)

Note: Check your patient’s eligibility and benefits in our provider portal (availity.com)** to verify coverage for these new benefits.

Details on new enhanced benefits

Ambulance services without transport: Currently, if a member or another person calls for an ambulance for a member’s health emergency, and the member isn’t transported, the service isn’t covered. Beginning Jan. 1, 2024, if the ambulance providers are able to stabilize the member at the current location without transporting to a facility, the plan covers the services with the applicable cost sharing. This service isn’t covered outside of the U.S. or its territories.

Enhanced annual wellness visit: After having Medicare Part B for longer than 12 months, members can get an annual wellness visit every 12 months.

The annual wellness visit:

  • Can help members develop or update a personalized prevention plan based on their current health and risk factors
  • Allows them to get the visit anytime throughout a calendar year, regardless of the date of the previous year’s visit

No cost sharing applies for this benefit.

Mobile crisis and crisis stabilization for behavioral health: This benefit offers improved care for people experiencing a behavioral health crisis. Services include mobile crisis intervention by eligible providers through telehealth or face-to-face, on-site services and crisis stabilization. Members can be treated at their home or another location, and at participating outpatient psychiatric centers available in certain counties in Michigan. Cost sharing applies for these services. For more information on crisis care services and locations, visit our crisis care webpage.

Availity is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to offer provider portal services.

**Blue Cross Blue Shield of Michigan doesn’t own or control this website.


We’re making some changes in behavioral health processes beginning Jan. 1

What you need to know

New Directions, now known as Lucet, won’t handle requests for Blue Cross Blue Shield of Michigan commercial members related to dates of service before Jan. 1, 2024, a change from what was originally published.

Submit requests for prior authorization, continued stay reviews and appeals related to dates of service before Jan. 1, 2024, using one of these methods:

When contacting Blue Cross by email or phone, you’ll need to provide the following:

  • Your name
  • Contact number
  • Member name
  • Member date of birth
  • Contract number
  • Date of service

We communicated in previous articles that starting Jan. 1, 2024, Blue Cross Blue Shield of Michigan and Blue Care Network will consolidate the prior authorization and case management functions for behavioral health services, including treatment for autism.

This will affect all members covered by Blue Cross commercial, Medicare Plus Blue℠, BCN commercial and BCN Advantage℠ plans, except those in certain employer groups. Refer to the Mental Health and Substance Use Disorder Carve-Out List for more information.  

The programs are called:

  • Blue Cross Behavioral Health℠, which will manage prior authorizations for behavioral health services, including treatment for autism
  • Blue Cross® Coordinated Care℠, which will handle behavioral health case management

These programs will align and standardize prior authorization and case management functions for Blue Cross and BCN members. We expect this consistency across lines of business to simplify processes for health care providers.

Consistent processes

The main benefit for providers is consistency across all lines of business. For example, for dates of service on or after Jan. 1, 2024:

  • You’ll use a new provider portal to submit prior authorization requests for all affected Blue Cross and BCN members.
  • For autism treatment services, we’ll be revising the requirement to obtain an evaluation through an approved autism evaluation center. (Watch for future communications on this topic.)

FAQ document

We’ve published the Blue Cross Behavioral Health: Frequently asked questions for providers document, which contains many details you’ll need to know.

In the FAQ document, you’ll find important information that will help you navigate this change, including how to submit requests for prior authorization, continued stay reviews and appeals for all dates of service.

We’ll update the FAQ document with additional information as it becomes available.

Key change for Blue Cross commercial prior authorization requests

Starting Jan. 1, 2024, New Directions, now known as Lucet, won’t handle requests for Blue Cross commercial members with dates of service on or after Jan. 1, 2024.

Also, Lucet won’t handle requests related to dates of service before Jan. 1, 2024, a change from what was originally published.

For Blue Cross commercial members, submit requests for prior authorization, continued stay reviews and appeals related to dates of service before Jan. 1, 2024, using one of these methods:

When you email or call, provide:

  • Your name and a contact phone number for you
  • The member’s name and contract number
  • The date of service you’re inquiring about
  • A brief description of what you’re requesting (for example, prior authorization, continued stay review or appeal)

Medical necessity criteria

For dates of service on or after Jan. 1, 2024, Blue Cross Behavioral Health will use the following to make determinations on prior authorization requests:

  • Level of Care Utilization System, or LOCUS®, criteria
  • Child and Adolescent Level of Care Utilization System, or CALOCUS®, criteria
  • Early Childhood Services Intensity Instrument, or ECSII, criteria
  • The ASAM Criteria®, from the American Society of Addiction Medicine
  • Blue Cross and BCN medical policy for transcranial magnetic stimulation 

Later in 2023, you’ll be able to access these criteria on our Services That Need Prior Authorization webpage at bcbsm.com.

Appeals process

Starting in 2024, the addresses for submitting appeals of prior authorization requests that aren’t approved will change. Refer to the determination letters for the addresses.

Training

We’ll offer training for providers to learn how to access and use the new provider portal to submit prior authorization requests. Watch for more information.


Washtenaw County Community Mental Health joins crisis services program

Washtenaw County Community Mental Health is the newest organization to join Blue Cross Blue Shield of Michigan’s crisis services program. It offers both mobile crisis and residential crisis services.

For mobile crisis services or to determine the location of the appropriate facility for the member, call 734-544-3050.

Our crisis services program was designed to offer our members (and their family members) a wider array of care options if they’re experiencing a mental health crisis.

To learn more about the program and to see a list of other participating facilities, visit the Crisis Care section of our behavioral health website.


Here are some claim editing reminders

CPT Category II codes: The lab codes below require a CPT Category II code when you’re providing test results and the test was performed in an office location. CPT Category II codes are a set of tracking codes that can be used to measure performance. They may be used to describe results from clinical laboratory or radiology tests and other procedures intended to address patient safety issues.

*80061 — Lipid panel. This panel must include the following:

  • Cholesterol, serum, total (*82465)
  • Lipoprotein, direct measurement; HDL cholesterol (*83718)
  • Triglycerides (*84478)

*83036 — Hemoglobin; glycosylated (A1c)
*83721— Lipoprotein, direct measurement; LDL cholesterol

Claims that are submitted without the associated CPT Category II code may undergo claim editing and be denied. If you receive a claim denial, submit a corrected claim with the appropriate Category II code, not an appeal.

New patient visit edits: A new patient is one who hasn’t received any professional services from the physician or another physician of the same specialty who belongs to the same group practice within the past three years. Prior visits are those indicated with evaluation and management codes or other face-to-face professional services billed within a three-year period. A face-to-face professional service includes E&M codes, surgical procedures and other procedures or services. Only one new patient visit is allowed in a three-year period.

New patient claims that are submitted within three years of a prior new patient visit or any face-to-face service may be denied. If you receive a claim denial, submit a corrected claim using the appropriate established patient E&M code, not an appeal.

None of the information included in this article is intended to be legal advice and, as such, it remains the provider’s responsibility to ensure that all coding and documentation are done in accordance with all applicable state and federal laws and regulations.


Reminder: Signature required on medical records

What you need to know

Medical records require a provider’s signature. This article reviews what constitutes acceptable electronic and handwritten signatures.

  • Electronic signatures must include a name, date, credentials and attestation statement.
  • Handwritten signatures must include a legible signature, including credential. An illegible signature is allowed when provided on letterhead or other information on the page identifies the signer’s identity.

A signature is mandatory on medical records to identify who provided services for the patient. It also validates the services were documented, reviewed and authenticated by the provider.

Requirements for an acceptable signature depend on whether the medical record is generated by an electronic health record or is handwritten.

Services performed by nonphysician practitioners who require physician supervision must be signed by the overseeing provider. Examples of services requiring a supervising physician signature include therapeutic and behavioral health. This includes providers supervising licensed social workers, behavioral health therapists, massage therapists and registered nurses performing administration of drugs.

Electronic signatures

Electronic signatures must be generated by encrypted or password-protected software and used solely by the author of the report or record.

The Medicare Integrity Manual (Ch. 3, 3.3.2.4) states:

“Providers using electronic systems need to recognize that there is a potential for misuse or abuse with alternate signature methods. For example, providers need a system and software products that are protected against modification, etc., and should apply adequate administrative procedures that correspond to recognized standards and laws. The individual whose name is on the alternate signature method and the provider bear the responsibility for the authenticity of the information for which an attestation has been provided. Physicians are encouraged to check with their attorneys and malpractice insurers concerning the use of alternative signature methods.”

Electronic signatures must contain the following key elements:

  • Practitioner’s name
  • Credentials
  • Date
  • Printed attestation statement

Acceptable attestation statements include the following:

  • Accepted by
  • Acknowledged by
  • Approved by
  • Authenticated by
  • Closed by
  • Digitally signed by
  • Electronically authored by
  • Finalized by
  • Generated by
  • Released by
  • Reviewed by
  • Signed by
  • Validated by
  • Performed by (when exam and related documentation are performed by the same provider)

Example (electronic signature and attestation statement):

  • Electronically signed by: Eli Carson, M.D. 09/18/2023
  • Approved by: Peter Wilsby, NP 08/23/2023

Unacceptable electronic signatures include the following:

  • Signature on file
  • Electronically signed by agent of provider
  • Signed but not read
  • Electronically signed, but not authenticated
  • Electronically signed, but not validated or verified

Examples:

  • Electronically signed, but not authenticated George Hudson, M.D.
  • Peter Cunningham, M.D. 07/14/2023
  • Signed Jessica Kastle (No credentials)

Handwritten signatures

Handwritten signatures may only be used on handwritten, transcribed or dictated reports. Handwritten signatures aren’t valid on reports generated from an electronic health records system.
 
A handwritten signature is acceptable if it is:

  • A fully legible signature, including credential
  • A legible first initial, last name and credential
  • An illegible signature, or initials, when over a typed or printed name and credential
  • An illegible signature when the letterhead or other information on the page indicates the identity and credential of the signer

The Medicare Program Integrity Manual (Chapter 3) requires a handwritten signature be legible and include the provider’s credentials. An illegible signature is allowed when the letterhead or other information on the page indicates the identity and credential of the signer.

For additional guidance, refer to the Medicare Program Integrity Manual** and the June 2018 Record article, Medical Record Signatures: What’s acceptable?

**Blue Cross Blue Shield of Michigan doesn’t own or control this website.


Update: Starting Jan. 1, 2024, all DME codes will be removed from the CareCentrix HIT and AIS program

This is an update to previous newsletter articles on this topic that ran in The Record and BCN Provider News. The articles contained three incorrect HCPCS codes. Use the following article as your reference going forward.

For dates of service on or after Jan. 1, 2024, the durable medical equipment codes listed in the table below will be removed from the CareCentrix network management program for home infusion therapy and ambulatory infusion suite providers.

HCPCS codes

B4034

B4035

B4036

B4081

B4082

B4083

B4087

B4102

B4103

B4104

B4105

B4149

B4150

B4152

B4153

B4154

B4155

B4157

B4158

B4159

B4160

B4161

B4162

B4185

B4187

B9002

B9998

 

 

 

This change applies to:

  • Blue Cross Blue Shield of Michigan and Blue Care Network commercial members
  • Independent home infusion therapy and ambulatory infusion suite providers
    Note: Ambulatory infusion suite providers are a subset of ambulatory infusion centers.

These codes are still part of the DME benefit. Providers who participate in Blue Cross’ or BCN’s DME network can bill them in accordance with existing Blue Cross or BCN billing guidelines.

Prior to Jan. 1, 2024, we’ll update the Home infusion therapy and ambulatory infusion suite provider network management: Frequently asked questions document to reflect this change.

CareCentrix is an independent company that manages the in-state, independent home infusion services and ambulatory infusion center provider network for Blue Cross Blue Shield of Michigan and Blue Care Network members who have commercial plans.


Northwood to manage outpatient diabetes supplies for some members, starting Jan. 1

Starting Jan. 1, 2024, Northwood Inc., an independent company, will manage outpatient diabetes supplies that are covered under the medical benefit for members with:

  • Medicare Plus Blue℠
  • Blue Care Network commercial
  • BCN Advantage℠

For these members, Northwood will:

  • Maintain the statewide provider network for durable medical equipment and prosthetic and orthotic supplies and services.
  • Receive and make determinations on prior authorization requests.
  • Process and pay claims for covered services.

Outpatient diabetes supplies include items such as continuous glucose monitors, insulin pumps and supplies, and testing supplies.

Contact Northwood starting Jan. 1

Starting Jan. 1, for diabetes supplies for Medicare Plus Blue, BCN commercial and BCN Advantage members, health care providers can call Northwood's Customer Service department at 1 800-393-6432 to locate the nearest supplier contracted with Northwood. The contracted supplier will:

  • Submit the prior authorization requests to Northwood for review.
  • Submit the claims directly to Northwood.

Providers who currently submit orders directly to J&B Medical may continue to do so. J&B Medical is an independent company that participates in the Northwood network.


Some diabetes drugs to require prior authorization for Blue Cross and BCN members, starting Jan. 1

Beginning Jan. 1, 2024, the presence of prior pharmacy claims for insulin alone will no longer qualify Blue Cross Blue Shield of Michigan commercial and Blue Care Network commercial members for coverage of the medications in the table listed below. We’ll require a prior authorization to confirm that the medications listed below are being used for Type 2 diabetes for members who don’t have a supporting prescription or medical record with a diabetes diagnosis.

The full-coverage requirements are listed in the table below.

Brand-name medication

FDA-approved indication

Coverage requirements starting Jan. 1

Bydureon®
Byetta®
Mounjaro®
Ozempic®

Rybelsus®
Trulicity®
Victoza®

 

 

 

 

 

 

Type 2 diabetes

Coverage without prior authorization will require diagnosis of Type 2 diabetes verified by one of the following:

  • Trial of one generic or preferred medication for the treatment of Type 2 diabetes within the prior 12-month period, except for metformin, GLP-1 receptor agonist, or insulin**
  • Diagnosis code for Type 2 diabetes identified in medical claim history within the prior 24-month period

If either coverage criteria outlined above isn’t fulfilled, you must submit a prior authorization to confirm that your patient has a diagnosis of Type 2 diabetes for coverage.

**Effective Jan. 1, 2024, previous trial of only insulin will no longer qualify members for coverage without prior authorization if they don’t have a medical diagnosis of Type 2 diabetes.

For more information on how to submit an authorization electronically:

  1. Go to ereferrals.bcbsm.com.
  2. Select Blue Cross for PPO members or BCN for HMO members.
  3. Click on Pharmacy Benefit Drugs on the left.
  4. Scroll down to How to submit an electronic prior authorization, or ePA, request

A complete list of included drugs and coverage requirements for all drug lists is available at bcbsm.com/druglists.


Blue Cross and BCN covering additional vaccines

To increase access to vaccines and decrease the risk of vaccine-preventable disease outbreaks, Blue Cross Blue Shield of Michigan and Blue Care Network will add the following vaccines to our list of vaccines covered under the pharmacy benefit:

  • Pfizer COVID-19 vaccine (2023-2024), 6 months to 4 years old
  • Pfizer COVID-19 vaccine (2023-2024), 5 to 11 years old
  • Novavax COVID-19 vaccine (2023-2024)
  • Comirnaty, Pfizer COVID-19 vaccine (2023-2024)
  • Spikevax, Moderna COVID-19 vaccine (2023 -2024)

For information about the procedure codes to use when billing for these vaccines, see the article “Updated COVID-19 vaccines approved by FDA,” also in this issue.

Vaccine list

Following is a list of all the vaccines that are covered under eligible members’ prescription drug plans. Most Blue Cross and BCN commercial (non-Medicare) members with prescription drug coverage are eligible. If a member meets the coverage criteria, the vaccine is covered with no cost sharing.

Vaccines that have an age requirement

Vaccine

Common name and abbreviation

Age Requirement

Gardasil 9®

Human papillomavirus vaccine – HPV

9 to 45 years old

Influenza virus

Influenza vaccine – Flu

Younger than 9: 2 vaccines per 180 days
9 and older: 1 vaccine per 180 days

Prevnar 13®

Pneumococcal 13 – valent conjugate vaccine

65 and older

Vaccines that have no age requirement

Vaccine

Common name and abbreviation

  • Dengvaxia®

Dengue vaccine – DEN4CYD

  • Daptacel®
  • Infanrix®

Diphtheria, tetanus, and acellular pertussis vaccine – DTaP

  • Diphtheria and Tetanus Toxoids

Diphtheria, tetanus vaccine – DT

  • Kinrix®
  • Quadracel®

DTap and inactivated poliovirus vaccine – DTaP-IPV

  • Pediarix®

DTaP, hepatitis B, and inactivated poliovirus vaccine – DTaP-HepB-IPV

  • Vaxelis®

DTaP, inactivated poliovirus, Haemophilus influenzae type b, and hepatitis B vaccine – DTaP-IPV-Hib-HepB

  • ActHIB®
  • Hiberix®
  • PedvaxHIB®



Haemophilus influenzae type b vaccine – Hib

  • Havrix®
  • Vaqta®

Hepatitis A – HepA

  • Engerix-B®
  • Heplisav-B®
  • PreHevbrio™    
  • Recombivax HB®

Hepatitis B – HepB

  • Twinrix®

Hepatitis A & B – HepA-HEPB

  • M-M-R II®
  • Priorix®

Measles, mumps, rubella vaccine – MMR

  • ProQuad®

Measles, mumps, rubella and varicella vaccine – MMRV

  • Menveo®

Meningococcal serogroups A, C, W, Y vaccine – MenACWY-CRM

  • Menactra®

Meningococcal serogroups A, C, W, Y vaccine – MenACWY-D

  • MenQuadfi®

Meningococcal serogroups A, C, W, Y vaccine – MenACWY-TT

  • Bexsero®

Meningococcal serogroup B vaccine – MenB-4C

  • Trumenba®

Meningococcal serogroup B vaccine – MenB-FHbp

  • Vaxneuvance™

Pneumococcal 15-valent conjugate vaccine – PCV15

  • Prevnar 20™

Pneumococcal 20-valent conjugate vaccine – PCV20

  • Pneumovax 23®

Pneumococcal 23-valent polysaccharide vaccine – PPSV23

  • IPOL®

Poliovirus – IPV

  • Arexvy™
  • Abrysvo™

Respiratory syncytial virus – RSV

  • Rotarix®

Rotavirus vaccine – RV1

  • RotaTeq®

Rotavirus vaccine – RV5

  • Tdvax®
  • Tenivac®

Tetanus and diphtheria vaccine – Td

  • Adacel®
  • Boostrix®

Tetanus, diphtheria and acellular pertussis vaccine – Tdap

  • Varivax®

Varicella vaccine – VAR (chickenpox)

  • Shingrix®

Zoster vaccine – RZV (shingles)

COVID-19 vaccines

  • Pfizer COVID-19 vaccine (2023-2024), 6 months to 4 years
  • Pfizer COVID-19 vaccine (2023-2024), 5 to 11 years
  • Novavax COVID-19 vaccine (2023-2024)
  • Comirnaty, Pfizer COVID-19 vaccine (2023-2024)
  • Spikevax, Moderna COVID-19 vaccine (2023-2024)

Notes:

  • If a member doesn’t meet the age requirement for a vaccine, Blue Cross and BCN won’t cover the vaccine under the prescription drug plan, and the claim will reject.
  • Vaccines must be administered by certified, trained and qualified registered pharmacists.

Updated COVID-19 vaccines approved by FDA

The U.S. Food and Drug Administration recently amended the emergency use authorization of COVID-19 vaccines from Moderna,** Novavax** and Pfizer-BioNTech** to include the 2023-24 formula.

Use the following procedure codes for COVID-19 monovalent vaccine administration and products: *90480, *91304, *91318, *91319, *91320, *91321 and *91322. 

For more information, see the following:

The vaccine administration and products are part of members’ preventive benefits. For most health plans, there’s no member cost sharing. See below for information about checking vaccine benefits for Blue Cross Blue Shield of Michigan commercial groups that may have cost sharing or may not have vaccine coverage.

Blue Cross commercial groups that may have cost sharing or may not have vaccine coverage

For members who have coverage through Blue Cross commercial groups that are exempt from the Patient Protection and Affordable Care Act, members may have cost sharing or they may not have vaccine coverage.

Here’s how to check member eligibility and benefits for vaccines:

  1. Log in to our provider portal (availity.com).**
  2. Click on Patient Registration in the menu bar and then click on Eligibility and Benefits Inquiry.
  3. Enter the payer information and complete the fields in the Provider Information section.
  4. Complete the Patient Information section and click on Search.
  5. Select the row for the appropriate member.
  6. In the Service Information section, enter Immunizations in the Benefit/Service Type field.
  7. Click on Submit.
  8. Do one of the following:

If…

Then…

There is a Benefit Explainer button near the top of the screen

  1. Click on the Benefit Explainer button.
  2. Tip: If Benefit Explainer doesn’t open, you’ll need to allow Availity® Essentials to open popups.

  3. In Benefit Explainer, click on the Search button.
  4. Press CTRL+F.
  5. Search Preventive Immunizations.

There isn’t a Benefit Explainer button near the top of the screen

  1. Press CTRL+F.
  2. Search on Immunizations.

For more information on our vaccines, see the article “Blue Cross and BCN covering additional vaccines,” also in this issue.

None of the information included in this article is intended to be legal advice and, as such, it remains the provider’s responsibility to ensure that all coding and documentation are done in accordance with all applicable state and federal laws and regulations.

Availity® is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to offer provider portal and electronic data interchange services.

**Blue Cross Blue Shield of Michigan doesn’t own or control this website.


Requirements and codes changed for some medical benefit drugs

As part of our efforts to encourage appropriate use of high-cost medications covered under the medical benefit, we recently added requirements for some medical benefit drugs. Also, the Centers for Medicare & Medicaid Services assigned some drugs new HCPCS codes. The changes went into effect on various dates in July, August and September.

Changes in requirements

For Blue Cross Blue Shield of Michigan commercial and Blue Care Network commercial members, we added prior authorization requirements for the following:

HCPCS code

Brand name

Generic name

J3590**

Elevidys

Delandistrogene moxeparvovec-rokl

J3590**

Eylea® HD

Aflibercept

J3590**

Izervay™

Avacincaptad pegol

J3590**

Lantidra™

Donislecel-jujn

J3590**

Roctavian™

Waloctocogene roxaparvovec-rvox

J3590**

Rystiggo®

(Rozanolixizumab-noli)

J3590**

Tyruko®

Natalizumab-sztn

J3590**

Veopoz™

Pozelimab-bbfg

J3590**

Vyvgart® Hytrulo

(Efgartigimod alfa and hyaluronidase-qvfc)

For Medicare Plus Blue℠ and BCN Advantage℠ members, we added prior authorization requirements for the following:

HCPCS code

Brand name

Generic name

For dates of service on or after

J3590**

Elevidys

Delandistrogene moxeparvovec-rokl

July 10, 2023

J3590**

Roctavian™

Valoctocogene roxaparvovec-rvox

July 10, 2023

J3590**

Rystiggo®

Rozanolixizumab-noli

July 10, 2023

J3490**

Vyvgart® Hytrulo

Efgartigimod alfa and hyaluronidase-qvfc

July 10, 2023

J3590**

Qalsody™

Tofersen

Aug. 1, 2023

J3590**

Elfabrio®

Pegunigalsidase alfa-iwxj

Aug. 14, 2023

J3590**

Vyjuvek™

Beremagene geperpavec-svdt

Aug. 14, 2023

J3590**

Veopoz™

Pozelimab-bbfg

Sept. 1, 2023

Code changes

The table below shows HCPCS code changes that were effective July 1, 2023, (unless otherwise noted) for medical benefit drugs we manage.

New HCPCS code

Brand name

Generic name

J1440

Rebyota™

Fecal microbiota, live-jslm

J1576

Panzyga®

Immune globulin Intravenous (human) – ifas 10%

J9381

Tzield®

Teplizumab-mzwv

J9029

Adstiladrin®

Nadofaragene firadenovec-vncg

J0174 (effective July 6, 2023)

Leqembi®

Lecanemab-irmb

Drug lists

For additional details, see the following drug lists:

These lists are also available on the following pages of the ereferrals.bcbsm.com website:

More information about these requirements

We communicated these changes previously through provider alerts. Those alerts contain additional details.

You can view the provider alerts on ereferrals.bcbsm.com and on our Provider Resources site, which is accessible through our provider portal (availity.com).***

More information for Blue Cross commercial groups

For Blue Cross commercial groups, authorization requirements apply only to groups that participate in the standard commercial Medical Drug Prior Authorization Program for drugs administered under the medical benefit. To determine whether a group participates in the prior authorization program, see the Specialty Pharmacy Prior Authorization Master Opt-in/out Group list. A link to this list is also available on the Blue Cross Medical Benefit Drugs page of the ereferrals.bcbsm.com website.

Note: Blue Cross and Blue Shield Federal Employee Program® members and UAW Retiree Medical Benefits Trust (non-Medicare) members don't participate in the standard prior authorization program

Reminder

An authorization approval isn’t a guarantee of payment. As always, health care providers need to verify eligibility and benefits for members.

Availity® is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to offer provider portal and electronic data interchange services.

**May be assigned a unique code in the future.

***Blue Cross Blue Shield of Michigan and Blue Care Network doesn’t own or control this website.


Starting Jan. 1, we’ll change how we cover some drugs on Clinical, Custom, Custom Select and Preferred drug lists

Our goal at Blue Cross Blue Shield of Michigan and Blue Care Network is to provide our members with safe, high-quality prescription drug therapies. We continually review prescription drugs so we can provide the best value for our members, control costs and make sure our members are using the right drugs for the right situations.

Starting Jan. 1, 2024, we’ll change how we cover some medications on the Clinical, Custom, Custom Select and Preferred drug lists. We’ll send letters to notify affected members, their groups and their health care providers about these changes.

Drugs that won’t be covered on the Clinical, Custom and Custom Select Drug lists
We’ll no longer cover the drugs listed in the table below. Unless noted, both the brand name and available generic equivalents won’t be covered. If a member fills a prescription for one of these drugs on or after Jan. 1, 2024, they’ll be responsible for the full cost.

The drugs that won’t be covered are listed along with suggested covered preferred alternatives that have similar effectiveness, quality and safety. When pharmacies fill prescriptions with preferred alternatives, the generic equivalents are dispensed, if available. Additional coverage requirements may apply for preferred alternatives, such as prior authorization.

Drugs that won’t be covered

Affected drug lists

Common use or drug class

Preferred alternatives

Generic doxycycline monohydrate 75mg capsule

Custom Select

Tetracycline antibiotic

  • Generic doxycycline hyclate capsule; 100mg tablet
  • Generic doxycycline monohydrate 50mg, 100mg capsule; 50mg, 75mg, 100mg tablet

APO-varenicline

Clinical, Custom, Custom Select

Smoking cessation

Generic varenicline tartrate (Chantix®)

Copaxone® 20mg/mL
(brand glatiramer)

Custom Select

Multiple sclerosis

Generic glatiramer 20mg/mL, 40mg/mL (Glatopa®)

Drugs that will have a higher copayment on Clinical, Custom and Custom Select drug lists

The brand-name drugs that will have a higher copayment are listed in the table below along with suggested covered preferred alternatives that have similar effectiveness, quality and safety. When pharmacies fill prescriptions with preferred alternatives, the generic equivalents are dispensed, if available. Additional coverage requirements may apply for preferred alternatives.

Drugs that will have a higher copayment**

Affected drug lists

Common use or 
drug class

Preferred alternatives

Generic doxycycline monohydrate 75mg capsule

Custom
(HMO only)

Tetracycline antibiotic

  • Generic doxycycline hyclate capsule; 100mg tablet
  • Generic doxycycline monohydrate 50mg, 100mg capsule; 50mg, 75mg, 100mg tablet

Generic doxycycline monohydrate 150mg tablet

Custom
(HMO only)
Custom Select (HMO only)

Copaxone® 20mg/mL
(brand glatiramer)

Clinical, Custom

Multiple sclerosis

Generic glatiramer 20mg/mL, 40mg/mL (Glatopa®)

**Nonpreferred brand drugs aren’t covered for members with a closed benefit.

Brand-name drugs no longer covered with generic copay on HMO Custom Drug List

On some of our drug lists, select brand-name drugs are covered at a generic copay and the generic equivalent drug isn’t covered. These brand-name drugs will no longer be covered at the generic copay. Members can fill prescriptions with the generic equivalent.

Brand-name drug

Affected drug lists

Covered generic equivalent

Adderall® XR

Custom
(HMO only)

Dextroamphetamine/ amphetamine ER capsule

Drugs that won’t be covered on the Preferred Drug List

We’ll no longer cover the drugs in the table below. Unless noted, both the brand name and available generic equivalents won’t be covered. If a member fills a prescription for one of these drugs on or after Jan.1, 2024, they’ll be responsible for the full cost.

The drugs that won’t be covered are listed in the table below along with suggested covered preferred alternatives that have similar effectiveness, quality and safety. When pharmacies fill prescriptions with preferred alternatives, the generic equivalents are dispensed, if available. Additional coverage requirements may apply for preferred alternatives, such as prior authorization.

Drugs that won’t be covered

Common use or drug class

Preferred alternatives

Adhansia XR®

Attention-deficit/hyperactivity disorder (ADHD)

  • Generic methylphenidate (such as Ritalin® LA, Concerta®)
  • Generic dexmethylphenidate (such as Focalin® XR)
  • Generic amphetamine/ dextroamphetamine (such as Adderall® XR)
  • Lisdexamphetamine (Vyvanse®)

Aklief®, Arazlo®

Acne vulgaris

  • Generic adapalene 0.1% cream, gel (Differin®)
  • Generic adapalene-benzoyl peroxide gel 0.1-2.5% (Epiduo®)
  • Generic tazarotene 0.1% cream, gel (Tazorac®)

Aplenzin®, Forfivo XL®, bupropion ER 450mg (authorized brand alternative for Forfivo XL®)

Depression

Generic bupropion ER (Wellbutrin® SR/XL)

APO-varenicline

Smoking cessation

Generic varenicline tartrate (Chantix®)

Copaxone® 20mg/mL (brand glatiramer)

Multiple sclerosis

Generic glatiramer 20mg/mL, 40mg/mL (Glatopa®)

Generic dapsone 7.5% gel (Aczone®)

Acne vulgaris

Generic dapsone 5% gel (Aczone®)

Evekeo ODT®

Attention-deficit/hyperactivity disorder – ADHD

  • Generic dextroamphetamine solution (ProCentra®)
  • Generic methylphenidate solution, chewable tablet (Methylin®)

FloLipid®

Hypercholesterolemia

  • Generic statin (such as rosuvastatin (Crestor®)
  • Fluvastatin (Lescol XL®)
  • Atorvastatin (Lipitor®)
  • Pravastatin (Pravachol®)
  • Simvastatin (Zocor®)

Impoyz®

High-potency topical steroid

Generic high-potency topical steroid (such as betamethasone 0.5% cream, lotion; desoximetasone 0.25% cream, diflorasone 0.5% cream, flucinonide 0.5% cream, lotion; halcinonide 0.1% cream)

Lexette®, Ultravate® 0.05% lotion

Ultra-high-potency topical steroid

Generic ultra-high-potency topical steroid (such as clobetasol 0.05% cream, foam, spray; flucinonide 0.1% cream, halobetasol 0.05% cream, lotion)

Kristalose® packet

Constipation

Generic lactulose oral solution

Generic meclizine 50mg tablet

Vertigo, motion sickness

Generic meclizine 12.5mg, 25mg tablet

Ortikos®

Crohn’s disease

Generic budesonide 3mg capsule

Osmolex ER®

Parkinson’s disease

Generic amantadine tablet, solution

Oxaydo®

Pain

Generic oxycodone tablet

Phenergan Fortis® 25mg/5mL syrup

Nausea and vomiting

Generic promethazine 6.25mg/5mL syrup

Roszet®

Hypercholesterolemia

Generic ezetimibe (Zetia®) plus generic rosuvastatin (Crestor®)

Sernivo®

Moderate-potency topical steroid

Generic moderate-potency topical steroid (such as betamethasone 0.12% foam, desoximetasone 0.05% cream, fluticasone 0.05% cream, lotion; mometasone 0.1% cream, lotion; triamcinolone 0.2% spray)

Sprix®

Pain

Generic ketorolac tablet, injection

Generic tavaborole (Kerydin®)

Onychomycosis (nail fungus)

Ciclodan topical solution

Teriparatide 620 mcg/2.48mL injection

Osteoporosis

Forteo®, Tymlos®

Tosymra®

Migraine

  • Generic triptan (such as sumatriptan nasal spray (Imitrex®)
  • Zolmitriptan 5mg nasal spray (Zomig®)
  • Orally disintegrating tablet (Zomig ZMT®)
  • Rizatriptan orally-disintegrating tablet (Maxalt-ODT®)

Wynzora®

Plaque psoriasis

  • Generic calcipotriene/betamethasone ointment (Taclonex®)
  • Generic tazarotene 0.1% cream (Tazorac®)
  • Enstilar®

Xerese®

Herpes labialis (cold sores)

Generic acyclovir 5% ointment

Zilxi®

Rosacea

  • Generic azelaic 15% gel (Finacea®)
  • Generic metronidazole 0.75% cream, lotion (MetroCream®, MetroLotion®)
  • Finacea® foam

Drugs that will have a higher copayment on the Preferred Drug List

The brand-name drugs that will have a higher copayment are listed along with suggested covered preferred alternatives that have similar effectiveness, quality and safety. When pharmacies fill prescriptions with preferred alternatives, the generic equivalents are dispensed, if available. Additional coverage requirements may apply for preferred alternatives.

Drugs that will have a higher copayment

Common use or 
drug class

Preferred alternatives

Nulev®

Gastrointestinal conditions

Generic hyoscyamine sulfate 0.125mg, 0.375mg tablet (Such as Levsin®, Levbid®)

Sucraid®

Congenital sucrase-isomaltase deficiency

Discuss treatment options with your provider.

Xywav®

Narcolepsy, Idiopathic hypersomnia

Discuss treatment options with your provider.

Zomig® 2.5mg nasal spray

Migraine

  • Generic triptan (such as sumatriptan nasal spray (Imitrex®)
  • Zolmitriptan 5mg nasal spray (Zomig®)
  • Orally disintegrating tablet (Zomig ZMT®)
  • Rizatriptan orally disintegrating tablet (Maxalt-ODT®)

Brand-name drugs with a generic copay that won’t be covered on the Preferred Drug List

On some of our drug lists, select brand-name drugs are covered at a generic copay and the generic equivalent drug isn’t covered. These brand-name drugs will no longer be covered at the generic copay. Members can fill prescriptions with the generic equivalent, and the brand-name drug will no longer be covered.

Brand-name drug

Covered generic equivalent

Adderall® XR

Dextroamphetamine/ amphetamine ER capsule

Advair® Diskus®

Fluticasone propionate/salmeterol Diskus, Wixela® Inhub®

Firazyr®

Icatibant acetate injection

Lialda®

Mesalamine 1.2 g tablet

Targretin® capsule

Bexarotene capsule

Targretin® gel

Bexarotene gel


Changes coming to preferred drug designations under medical benefit for most commercial members

For dates of service on or after Jan. 1, 2024, Blue Cross Blue Shield of Michigan and Blue Care Network are making changes to preferred drug designations for some products. In addition, providers will need to submit prior authorization requests through different systems for some preferred and nonpreferred drugs.

These changes will affect:

  • Most Blue Cross commercial members
    • Exception: These changes don’t apply to UAW Retiree Medical Benefits Trust non-Medicare members or Blue Cross and Blue Shield Federal Employee Program® members.
  • All BCN commercial members

Changes to preferred drug designations

We’re changing preferred drug designations as shown in the following table. Changes are in bold text.

Product

Preferred drugs

Before Jan. 1, 2024

On or after Jan. 1, 2024

Bevacizumab

  • Mvasi®
  • Zirabev®

Mvasi only

Pegfilgrastim

  • Fulphila
  • Neulasta®, Neulasta® OnPro®
  • Ziextenzo®
  • Neulasta, Neulasta OnPro
  • Nyvepria®

Rituximab

  • Riabni™
  • Ruxience®
  • Ruxience
  • Truxima®

Trastuzumab

  • Kanjinti®
  • Trazimera®
  • Kanjinti
  • Ogivri®

How existing prior authorizations are affected by these changes

Existing prior authorizations are affected as follows:

  • For bevacizumab, rituximab and trastuzumab products, the member can continue taking a drug that will be designated as nonpreferred after Jan. 1 until their existing authorization expires. However, we encourage health care providers to begin using products that will be designated as preferred starting Jan. 1, 2024.
  • For pegfilgrastim products, active authorizations for Fulphila and Ziextenzo will end Dec. 31, 2023. Providers will need to transition members who are currently taking Fulphila or Ziextenzo to a preferred drug for dates of service on or after Jan. 1, 2024.

Changes to prior authorization processes

The following table outlines prior authorization requirements for the drugs listed above for dates of service on or after Jan. 1, 2024.

To determine which Blue Cross commercial groups have opted in to the Carelon medical oncology program, see the Carelon medical oncology prior authorization program opt-in list for Blue Cross commercial self-funded groups.

Lines of business

Changes to requirements

  • BCN commercial members
  • Blue Cross commercial members whose groups participate in the Carelon medical oncology program
  • Preferred drugs will require prior authorization through Carelon Medical Benefits Management.
  • Exception: Rituximab preferred drugs won’t require prior authorization.

  • Nonpreferred drugs will require prior authorization through NovoLogix. 

Blue Cross commercial members whose groups don’t participate in the Carelon medical oncology program

  • Preferred products won’t require prior authorization.
  • Nonpreferred products will require prior authorization through NovoLogix.  

Additional information

For additional information on requirements related to drugs covered under the medical benefit, refer to the following drug lists:

For additional information about medical benefit drugs, see the following pages of our ereferrals.bcbsm.com website:


We’ve updated how we calculate MME measurements for certain opioids

Blue Cross Blue Shield of Michigan and Blue Care Network have updated how we calculate morphine milligram equivalents, or MME, measurements for certain opioids. The update, based on changes recommended by the Centers for Disease Control and Prevention, was effective Oct. 1.

MMEs are calculations used to measure and compare different opioids, using morphine as the standard. Blue Cross requires a prior authorization for opioid dosages that exceed 90 MMEs per day. This change will only affect the opioids listed in the table below:

Medication

Current MME conversion factor

New MME conversion factor

Hydromorphone

4

5

Methadone

Sliding scale dependent on dose

4.7

Tramadol

0.1

0.2

Members who fill hydromorphone, methadone or tramadol prescriptions may experience a claim rejection when their total daily MME exceeds the plan threshold level of 90 MME, even if the member hasn’t changed doses. The total MME of all opioids remains at 90 MME per day and won’t change. 

If the pharmacy receives a rejected claim due to this change, the provider will need to submit a prior authorization request attesting that the dose is medically necessary. If we don’t provide a prior authorization, members may not be able to fill the prescribed dose.

For more information related to this change, refer to the Opioid National Drug Code and Oral MME Conversion File Update** on the CDC website.

**Blue Cross Blue Shield of Michigan doesn’t own or control this website.


Lumoxiti no longer requires prior authorization

Lumoxiti™ (moxetumomab pasudotox-tdfk), HCPCS code J9313, no longer requires prior authorization through Carelon Medical Benefits Management (formerly known as AIM Specialty Health®). This change applies to the following members for dates of service on or after Sept. 30, 2023:

  • Blue Cross Blue Shield of Michigan commercial
  • Medicare Plus Blue℠ members
  • Blue Care Network commercial members
  • BCN Advantage℠ members

This drug is covered under members’ medical benefits, not their pharmacy benefits.

More about prior authorization requirements

For information on requirements related to drugs covered under the medical benefit, refer to the following drug lists:

Carelon Medical Benefits Management is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to manage prior authorizations for select services.


Beyfortus to have quantity limits for commercial members, starting Jan. 1

Starting Jan. 1, 2024, Beyfortus™ (nirsevimab-alip), procedure codes *90380 and *90381, will have quantity limits when billed under the pharmacy benefit. There won’t be quantity limits when Beyfortus is billed under the medical benefit.

Note: For the administration of Beyfortus, use procedure codes *96380 and *96381.

Administration site and coverage details

Beyfortus is covered as follows.

Administration site

How it’s covered

Health care provider’s office

Under the medical benefit, with no quantity limits

Retail pharmacy when the member has pharmacy benefits through Blue Cross Blue Shield of Michigan or Blue Care Network

Under the pharmacy benefit

Quantity limits will apply

Retail pharmacy when both of the following are true:

  • The member doesn’t have pharmacy benefits through Blue Cross or BCN.
  • The pharmacy participates in the Blue Cross Vaccine Affiliation Program.

Under the medical benefit, with no quantity limits


Blue Cross commercial groups that may have cost sharing or may not have vaccine coverage

For members who have coverage through Blue Cross Blue Shield of Michigan commercial groups that are exempt from the Patient Protection and Affordable Care Act, members may have cost sharing or they may not have vaccine coverage.

Here’s how to check member eligibility and benefits for vaccines:

  1. Log in to our provider portal (availity.com).**
  2. Click on Patient Registration in the menu bar and then click on Eligibility and Benefits Inquiry.
  3. Enter the payer information and complete the fields in the Provider Information section.
  4. Complete the Patient Information section and click on Search.
  5. Select the row for the appropriate member.
  6. In the Service Information section, enter Immunizations in the Benefit/Service Type field.
  7. Click on Submit.
  8. Do one of the following:

If…

Then…

There is a Benefit Explainer button near the top of the screen

  1. Click on the Benefit Explainer button.
  2. Tip: If Benefit Explainer doesn’t open, you’ll need to allow
    Availity® Essentials to open popups.
  3. In Benefit Explainer, click on the Search button.
  4. Press CTRL+F.
  5. Search on Preventive Immunizations.

There isn’t a Benefit Explainer button near the top of the screen

  1. Press CTRL+F.
  2. Search on Immunizations.

None of the information included in this article is intended to be legal advice and, as such, it remains the provider’s responsibility to ensure that all coding and documentation are done in accordance with all applicable state and federal laws and regulations.

Availity® is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to offer provider portal and electronic data interchange services.

**Blue Cross Blue Shield of Michigan and Blue Care Network don’t own or control this website.


Zynyz to require prior authorization for most members, starting Dec. 10

For dates of service on or after Dec. 10, 2023, Zynyz™ (retifanlimab-dlwr), HCPCS code J9345, will require prior authorization through Carelon Medical Benefits Management (formerly known as AIM Specialty Health®).

The drug is covered under the members’ medical benefits, not their pharmacy benefits.

Prior authorization requirements apply when the drug is administered in outpatient settings for:

  • Blue Cross Blue Shield of Michigan commercial
    • All fully insured members (group and individual)
    • Members who have coverage through self-funded groups that have opted in to the Carelon medical oncology program. (Although UAW Retiree Medical Benefits Trust non-Medicare plans have opted in to this program, these requirements may not apply; refer to their medical oncology drug list, which is linked below.)
      Note: This requirement doesn’t apply to members who have coverage through the Blue Cross and Blue Shield Federal Employee Program®.
  • Medicare Plus Blue℠ members
  • Blue Care Network commercial members
  • BCN Advantage℠ members

How to submit authorization requests

Submit authorization requests to Carelon using one of the following methods:

  • Through the Carelon ProviderPortal, which you can access by doing one of the following:
    • Logging in to our provider portal (availity.com),** clicking on Payer Spaces and then clicking on the BCBSM and BCN logo. This takes you to the Blue Cross and BCN payer space where you’ll click on the Carelon ProviderPortal tile.
      Note: If you need to request access to our provider portal, see the Register for web tools webpage on bcbsm.com.
  • By calling the Carelon Contact Center at 1-844-377-1278

More about the prior authorization requirements

For additional information on requirements related to drugs covered under the medical benefit, refer to the following drug lists:

We’ll update the pertinent drug lists to reflect the information in this message prior to the effective date.
As a reminder, authorization isn’t a guarantee of payment. Health care practitioners need to verify eligibility and benefits for members.

Carelon Medical Benefits Management is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to manage prior authorizations for select services.

Availity® is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to offer provider portal and electronic data interchange services.

**Blue Cross Blue Shield of Michigan doesn’t own or control this website.


Starting Jan.1, prior authorization no longer required for some procedures

For dates of service on or after Jan. 1, 2024, the following procedures will no longer require prior authorization.

Note: For dates of service before Jan. 1, these procedures require prior authorization by Medicare Plus Blue℠ and BCN Utilization Management.

Procedure

Applies to

Affected procedure codes

Biofeedback, non-behavioral health

  • BCN commercial
  • BCN Advantage℠

*90901, *90912

Deep brain stimulation

  • Medicare Plus Blue
  • BCN commercial
  • BCN Advantage

*61863, *61864, *61867, *61868, *61880, *61885, *61886, *61888

Noncoronary vascular stents

  • Medicare Plus Blue
  • BCN commercial
  • BCN Advantage

*37236, *37238

Total artificial heart

  • BCN commercial
  • BCN Advantage

*0051T, *0052T, *0053T, *33927, *33928, *33975, *33976, *33977, *33978, *33979, *33980, *33981, *33982, *33983, *33990, *33991, *33992, *33993, *33995, *33997

Prior to Jan. 1, we’ll update lists of procedure codes that require prior authorization.

Prior to Jan. 1, we’ll update lists of procedure codes that require prior authorization.


Here’s an update on high-intensity in-home care program through Landmark

We’ve communicated extensively about the Landmark high-intensity in-home health care program in The Record over the past two years. This month, we want to bring you a quick overview of the program, along with a look at some of our program outcomes and what members are saying about the program.

Background

Blue Cross Blue Shield of Michigan and Blue Care Network launched the Landmark high-intensity in-home care program in late 2021 for eligible members in Southeast Michigan with coverage through a group customer. The program was expanded in phases and, since January 2023, it’s available to all eligible Medicare Plus Blue℠ and BCN Advantage℠ members who reside in Michigan’s Lower Peninsula.

Blue Cross and BCN offer this program as a benefit for our most at-risk members. This additional in-home support is also something employer groups have requested to help improve quality of life and health outcomes.

To be eligible for the Landmark program, members must have multiple chronic conditions and take a high number of prescription medications. Currently, approximately 15% of Blue Cross and BCN’s Medicare Advantage members are eligible.

How the Landmark program works

Using a physician-led, interdisciplinary team, the Landmark program complements office-based primary care by:  

  • Collaborating and coordinating with each member’s primary care provider, using the primary care provider’s preferred method of communication 
  • Supporting frail, elderly patients who want help managing their conditions through in-home care 
  • Delivering additional supportincluding medical, behavioral and urgent care; medication management, and 24/7 nurse triage when a member is unable to reach their primary care provider

The Landmark program provides supplemental support and reinforces the primary care provider’s plan of care for chronic condition management. It doesn’t replace a member’s primary care provider, and members don’t become attributed or assigned to Landmark. Because the Landmark program is part of members’ benefits, eligible members can choose whether they want to participate.

Program outcomes

We’re beginning to see the benefits of the Landmark program on this vulnerable member population.

Early data from the initial phase of the program has shown the following for engaged members:

  • An increase in primary care provider visits
  • A decrease in acute inpatient utilization after a period of time in the program 
  • High member satisfaction, with 96% rating it as excellent, very good or good

Collaborating with physician organizations

Landmark has built collaborative relationships with a number of physician organizations and is willing to adapt processes and communication methods to best meet the unique needs of each physician organization.

At a recent Physician Group Incentive Program meeting, Sparrow Care Network shared details of how they’re working with Landmark to build a successful collaboration, despite initial concerns from Sparrow providers about the program. The working relationship is being customized to fit into Sparrow’s overall Population Health Service Organization and requires engagement from clinical and operational teams from both organizations.

Sparrow care managers also play a significant role in ensuring communication flows appropriately in both directions. Sparrow has expressed appreciation for Landmark’s flexibility and responsiveness and continues to collaborate on achieving the best care outcomes for patients.

What members are saying about the Landmark program

Here are several comments from Blue Cross and BCN members who are engaged in the Landmark program:

I was in need of some help. My doctor wasn't available. Erica (nurse practitioner) arrived within a few hours. Erica was very friendly and professional. I am grateful for her help.”

“Wonderful experience. Very professional, but very caring. Very nice to have medical service at home.”

The nurses have been very good about responding to me when I get sick or fall. I'm grateful they're included in my insurance plan.”

“My father received excellent and immediate care in his home when his cold became more serious with shortness of breath, fever and productive cough. I was able to talk with the clinician by phone during the visit and all our concerns were addressed. Follow-up care was also excellent.”

“Great program for keeping my health at its best.”

How to learn more

To learn more about our program with Landmark, see the High-intensity in-home care program: Frequently asked questions for providers document.

If you have questions about the program, email the Blue Cross Care Delivery Solutions team at CareDeliverySolutionsProgramMtg@bcbsm.com.

To coordinate directly with Landmark regarding patient care, call Landmark at 313-241-5242.

Landmark Health LLC is an independent company that provides in-home care services for Blue Cross Blue Shield of Michigan and Blue Care Network members who have Medicare Advantage plans.


Newly enrolled PAs and NPs required to identify their work settings to help avoid payment issues

What you need to know

This requirement applies to newly enrolled physician assistants and nurse practitioners only. Work setting information for PAs and NPs enrolled prior to Nov. 10 will be updated automatically — there’s no action required.

Starting Nov. 10, 2023, newly enrolled physician assistants and nurse practitioners will be required to identify their work settings (primary care or specialty care) on our provider enrollment and change forms. This information is necessary to help ensure that withholds can be accurately applied and that payment issues can be resolved for PAs and NPs covering for physician specialists or primary care physicians.

The following provider enrollment and change forms have been updated to include work setting:

  • Allied Practitioner Enrollment Form
  • Allied Practitioner Change Form
  • New Group Enrollment Form
  • Group Change Form

Provider enrollment and change forms can be found in the Enrollment section of bcbsm.com/providers


Update: TurningPoint medical policies for musculoskeletal and pain management procedures

In an article in the September Record and the September-October BCN Provider News, we reported that Blue Cross Blue Shield of Michigan, Blue Care Network and TurningPoint Healthcare Solutions LLC added and updated TurningPoint medical policies for musculoskeletal and pain management procedures.

The newsletter articles linked to a provider alert for details. We’re letting you know that we updated the provider alert to:

  • Add the Intraosseous Basivertebral Nerve Ablation (Intracept) medical policy to the list of new TurningPoint medical policies.
  • Explain that the new and updated medical policies apply to prior authorization requests submitted on or after Oct. 1, 2023 — not to dates of service on or after Oct. 1, as previously reported.

View the updated provider alert for full details.

TurningPoint Healthcare Solutions LLC is an independent company that manages authorizations for musculoskeletal surgical and related procedures for Blue Cross Blue Shield of Michigan and Blue Care Network.


Reminder: Independent labs must provide advance notice to Blue Cross commercial members before providing noncovered services

Here’s information you need to know about providing noncovered services to Blue Cross Blue Shield of Michigan commercial members at outpatient laboratories.

Independent laboratories

Before receiving noncovered services at independent laboratories, Blue Cross commercial members must sign the Advance Notice of Member Responsibility form.

Prior to having members sign the form, be sure to familiarize yourself with the requirements under our Clinical Laboratory Agreement.

The language in this agreement states that independent laboratories may bill members for services that Blue Cross has deemed to be not medically necessary only when all of the following are true:

  • Each member must specifically agree to these conditions in advance:
    • The member acknowledges that Blue Cross won’t pay for specific services because they were deemed medically unnecessary.
    • The member consents to receiving the services before the services are provided.
    • The member assumes financial responsibility for the services.
    • The health care provider provides the member with an estimated cost for the services.
  • Each form must state that Blue Cross won’t pay for the specific services and must include a price estimate for each service.

To access the Advance Notice of Member Responsibility form: 

  1. Log in to our provider portal (availity.com).**
  2. Click on Payer Spaces in the menu, then click on the BCBSM and BCN logo.
  3. Click on the Resources tab.
  4. Click on the Secure Provider Resources (Blue Cross and BCN) link.
  5. On the Provider Resources site, click on Forms in the menu, then on click Prior Authorization.
  6. Click on the Advance Notice of Member Responsibility for GY or GZ modifiers (PDF) link.

Hospital laboratories

The Advance Notice of Member Responsibility form isn’t approved for use by hospital labs at this time. We’re currently reviewing the processes for hospital labs. Watch for an upcoming provider alert and Record article with more information.

Availity® is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to offer provider portal and electronic data interchange services.

**Blue Cross Blue Shield of Michigan doesn’t own or control this website.


Here’s information and resources to share with patients about flu vaccine

This is part of an ongoing series of articles focusing on the tools and resources available to help FEP members manage their health.

With flu season in full swing, we wanted to make sure you have the resources you need to help encourage your patients to get the flu shot.

Here are some resources from the Centers for Disease Control and Prevention:

Encouraging patients with chronic conditions to get the flu vaccine is especially important but can sometimes be challenging. The following are flyers you can share with patients:

For more information on Blue Cross and Blue Shield Federal Employee Program® benefits and resources, members and health care providers can call Customer Service at 1-800-482-3600 or go to fepblue.org.

**Blue Cross Blue Shield of Michigan doesn’t own or control this website.


University of Michigan retirees can join our Medicare Advantage plans, effective Jan. 1

University of Michigan retirees can choose either our Medicare Plus Blue℠ or BCN Advantage℠ plan, effective Jan. 1, 2024. These plans provide coverage for medical and surgical benefits. Magellan Rx, an independent company, administers the group’s prescription drug benefits.

How to recognize a U-M Medicare Advantage member

U-M retirees with Medicare Plus Blue plans will have Blue Cross Blue Shield of Michigan identification cards that indicate “Medicare Plus Blue Group PPO.” The group number is 007005187 and the alphanumeric prefix of the enrollee ID is X3L

See sample ID card below:


A close-up of a medical card  Description automatically generated

The U-M BCN Advantage plan is called U-M PremierCare Advantage, and the logo will be displayed at the top right. The ID card will indicate Blue Care Network of Michigan at the top left. The group number is 00124316, and the enrollee ID number will have an alpha prefix of XYK. The HMO-POS logo next to the MA suitcase image at the bottom center shows that members have a point-of-service option.

See sample ID card below:

A close-up of a document  Description automatically generated

Note: Providers should verify eligibility and coverage at every visit. To verify eligibility and check coverage, log in to our provider portal, Availity Essentials, at availity.com.**

Enhanced benefits

U-M Medicare Advantage members have some additional enhanced benefits not available to other groups. Visit Medicare Plus Blue PPO Enhanced Benefits Policies or BCN Advantage Enhanced Benefits Policies for more information.

What to know about prior authorization

Like our other Medicare Advantage plans, U-M Medicare Advantage benefits require prior authorization for all acute inpatient admissions and specified high-tech radiology services. Prior authorization is also required for skilled nursing, long-term acute care and inpatient rehabilitation admissions.

For information about prior authorization requirements, refer to the appropriate provider manual listed below:

Availity is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to offer provider portal services.

**Blue Cross Blue Shield of Michigan and Blue Care Network don’t own or control this website.


Updated on-demand training available: e-referral, risk adjustment, ICD-10-CM coding

Action item

Visit our provider training site to find updated resources on topics that are important to your role.

Provider Experience continues to offer training resources for health care providers and staff. Our on-demand courses are designed to help you work more efficiently with Blue Cross Blue Shield of Michigan and Blue Care Network.

We recently updated the following learning opportunities:

  • e-referral self-paced modules: There are now nine modules that cover everything from how to access the system to the detailed steps for submitting a prior authorization request. The updates include the new status note for inpatient authorization requests. Search “e-referral” to quickly locate the modules.
  • Risk adjustment and ICD-10-CM coding: Recently updated, this course is designed for all providers who bill Blue Cross commercial, BCN commercial, Medicare Plus Blue℠ and BCN Advantage℠. It reviews the structure and guidelines for ICD-10-CM, as well as several common conditions and how they’re coded, reflecting the 2023 coding updates. You’ll also be presented with examples and case studies for ICD-10-CM diagnosis coding. Search “icd“ to locate the course.

The goal of our provider training site is to enhance the training experience for health care providers and staff. Check out the dashboard regularly for announcements as we add more courses, including those with CME offerings.

To request access to the training site, complete the following steps:

  1. Open the registration page.
  2. Complete the registration. We recommend using the same email you use to communicate with Blue Cross for provider-related needs. This will become your login ID.
  3. Follow the link to log in.

If you need assistance creating your login ID or navigating the site, contact ProviderTraining@bcbsm.com.


Lunch and learn webinars for physicians and coders focus on risk adjustment, coding

As a reminder, we’re offering live, 30-minute educational webinars that provide updated information on documentation and coding for common challenging diagnoses. Webinars also include an opportunity to ask questions. 

Here’s our upcoming schedule and tentative topics for the webinars. Each session starts at noon Eastern time. Log in to the provider training website to register for sessions that work with your schedule.

Session date

Topic

Nov. 15

Coding chronic kidney disease and rheumatoid arthritis

Dec. 13

CPT coding scenarios for 2024

Registering for the provider training website

If you haven’t already registered for the provider training website, follow these steps:

  1. Click here to register.
  2. Complete the registration. We recommend using the same email you use to communicate with Blue Cross Blue Shield of Michigan for other needs. This will become your login ID.

Locating a session

Click here if you’re already registered for the provider training website. On the provider training website, look in the Event Calendar or use the search feature using the keyword “lunch” to quickly locate all 2023 sessions.

See the screenshots below for more details.

Previous sessions

You can also listen to previously recorded sessions. Check out the following:

Date

Topic

April 26

HCC and risk adjustment coding scenarios

May 17

Coding neoplasms

June 21

Coding diabetes and hypertension

July 19

Coding heart disease and vascular disease

Aug. 16

Medical Record Documentation and MEAT

Sept. 20

Coding Tips for COPD and asthma

Oct. 18

ICD-10-CM updates and changes for 2024

For more information

If you have any questions about the sessions, contact April Boyce at aboyce@bcbsm.com. If you have questions regarding a session or website registration, email ProviderTraining@bcbsm.com.

Facility

New enhanced benefits will be available to Medicare Advantage members in 2024

Medicare Plus Blue℠ and BCN Advantage℠ are adding three new enhanced benefits to their comprehensive Medicare Advantage plans for the 2024 plan year. Beginning Jan. 1, 2024, members can capitalize on the following new benefits:

  • Ambulance services without transport
  • Enhanced annual wellness visit
  • Mobile crisis and crisis stabilization for behavioral health (available for members who reside in select counties)

Note: Check your patient’s eligibility and benefits in our provider portal (availity.com)** to verify coverage for these new benefits.

Details on new enhanced benefits

Ambulance services without transport: Currently, if a member or another person calls for an ambulance for a member’s health emergency, and the member isn’t transported, the service isn’t covered. Beginning Jan. 1, 2024, if the ambulance providers are able to stabilize the member at the current location without transporting to a facility, the plan covers the services with the applicable cost sharing. This service isn’t covered outside of the U.S. or its territories.

Enhanced annual wellness visit: After having Medicare Part B for longer than 12 months, members can get an annual wellness visit every 12 months.

The annual wellness visit:

  • Can help members develop or update a personalized prevention plan based on their current health and risk factors
  • Allows them to get the visit anytime throughout a calendar year, regardless of the date of the previous year’s visit

No cost sharing applies for this benefit.

Mobile crisis and crisis stabilization for behavioral health: This benefit offers improved care for people experiencing a behavioral health crisis. Services include mobile crisis intervention by eligible providers through telehealth or face-to-face, on-site services and crisis stabilization. Members can be treated at their home or another location, and at participating outpatient psychiatric centers available in certain counties in Michigan. Cost sharing applies for these services. For more information on crisis care services and locations, visit our crisis care webpage.

Availity is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to offer provider portal services.

**Blue Cross Blue Shield of Michigan doesn’t own or control this website.


Know guidelines for trauma activation billing and reimbursement

Blue Cross Blue Shield of Michigan and Blue Care Network follow the National Uniform Billing Committee rules for billing and reimbursing trauma activation charges. Effective immediately, Blue Cross and BCN won’t reimburse providers for trauma activation charges when they’re billed outside of the NUBC guidelines on inpatient facility claims. This rule applies to all claims submitted for Blue Cross commercial and BCN commercial members.   

This reimbursement policy isn’t intended to affect patient care. Health care providers are expected to apply medical judgment when caring for all members.

Here’s how to bill trauma activation under NUBC guidelines:

  • Use revenue code 068x in conjunction with FL 14, Type of Admission/Visit code 05. In the event of trauma activation, the facility must have received a prearrival notification from a prehospital caregiver, such as a paramedic or other emergency medical services provider.
  • If the member wasn’t assigned a prehospital notification revenue code, 068X shouldn’t be billed. However, the member may be classified as experiencing trauma on the UB-04, using FL 14, Type of Admission/Visit code 05 when identifying the member for follow-up purposes.
  • Non-designated trauma centers shouldn’t use FL 14, type 5 or 068X when billing for trauma services.

In addition to NUBC guidance for appropriately billing trauma activation, there’s also trauma activation criteria set forth by the American College of Surgeons. Apply the ACS criteria in the prehospital setting to identify trauma patients who would benefit most from the highest level of trauma activation.

The minimum criteria to activate the highest level of trauma activation is based on ACS 2022 updates to Resources for Optimal Care of the Injured Patient.** It includes one or more of the following:

  • Confirmed blood pressure less than 90 mm hg at any time in adults, and age-specific hypotension in children
  • Gunshot wounds to the neck, chest or abdomen
  • Glasgow Coma Scale less than 9, with mechanism attributed to trauma
  • Transfer patients from another hospital who require ongoing blood transfusion
  • Patients intubated in the field and directly transported to a trauma center
  • Patients who have respiratory compromise or need an emergent airway
  • Transfer patients from another hospital with ongoing respiratory compromise (excludes patients intubated at another facility who are now stable from a respiratory standpoint)
  • Patients experiencing an emergency as determined by a physician

Revenue code 068X is only permitted for reporting trauma activation charges, and trauma centers and hospitals must be licensed, designated or authorized by the state. The revenue code a facility may bill is determined by the ACS designation. See table below for details:

Revenue code

Description

0681

Trauma Center Level 1

0682

Trauma Center Level II

0683

Trauma Center Level III

0684

Trauma Center Level IV

0689

Extend beyond Level IV, assigned by state or local authorities

**Blue Cross Blue Shield of Michigan doesn’t own or control this website.


We’re making some changes in behavioral health processes beginning Jan. 1

What you need to know

New Directions, now known as Lucet, won’t handle requests for Blue Cross Blue Shield of Michigan commercial members related to dates of service before Jan. 1, 2024, a change from what was originally published.

Submit requests for prior authorization, continued stay reviews and appeals related to dates of service before Jan. 1, 2024, using one of these methods:

When contacting Blue Cross by email or phone, you’ll need to provide the following:

  • Your name
  • Contact number
  • Member name
  • Member date of birth
  • Contract number
  • Date of service

We communicated in previous articles that starting Jan. 1, 2024, Blue Cross Blue Shield of Michigan and Blue Care Network will consolidate the prior authorization and case management functions for behavioral health services, including treatment for autism.

This will affect all members covered by Blue Cross commercial, Medicare Plus Blue℠, BCN commercial and BCN Advantage℠ plans, except those in certain employer groups. Refer to the Mental Health and Substance Use Disorder Carve-Out List for more information.  

The programs are called:

  • Blue Cross Behavioral Health℠, which will manage prior authorizations for behavioral health services, including treatment for autism
  • Blue Cross® Coordinated Care℠, which will handle behavioral health case management

These programs will align and standardize prior authorization and case management functions for Blue Cross and BCN members. We expect this consistency across lines of business to simplify processes for health care providers.

Consistent processes

The main benefit for providers is consistency across all lines of business. For example, for dates of service on or after Jan. 1, 2024:

  • You’ll use a new provider portal to submit prior authorization requests for all affected Blue Cross and BCN members.
  • For autism treatment services, we’ll be revising the requirement to obtain an evaluation through an approved autism evaluation center. (Watch for future communications on this topic.)

FAQ document

We’ve published the Blue Cross Behavioral Health: Frequently asked questions for providers document, which contains many details you’ll need to know.

In the FAQ document, you’ll find important information that will help you navigate this change, including how to submit requests for prior authorization, continued stay reviews and appeals for all dates of service.

We’ll update the FAQ document with additional information as it becomes available.

Key change for Blue Cross commercial prior authorization requests

Starting Jan. 1, 2024, New Directions, now known as Lucet, won’t handle requests for Blue Cross commercial members with dates of service on or after Jan. 1, 2024.

Also, Lucet won’t handle requests related to dates of service before Jan. 1, 2024, a change from what was originally published.

For Blue Cross commercial members, submit requests for prior authorization, continued stay reviews and appeals related to dates of service before Jan. 1, 2024, using one of these methods:

When you email or call, provide:

  • Your name and a contact phone number for you
  • The member’s name and contract number
  • The date of service you’re inquiring about
  • A brief description of what you’re requesting (for example, prior authorization, continued stay review or appeal)

Medical necessity criteria

For dates of service on or after Jan. 1, 2024, Blue Cross Behavioral Health will use the following to make determinations on prior authorization requests:

  • Level of Care Utilization System, or LOCUS®, criteria
  • Child and Adolescent Level of Care Utilization System, or CALOCUS®, criteria
  • Early Childhood Services Intensity Instrument, or ECSII, criteria
  • The ASAM Criteria®, from the American Society of Addiction Medicine
  • Blue Cross and BCN medical policy for transcranial magnetic stimulation 

Later in 2023, you’ll be able to access these criteria on our Services That Need Prior Authorization webpage at bcbsm.com.

Appeals process

Starting in 2024, the addresses for submitting appeals of prior authorization requests that aren’t approved will change. Refer to the determination letters for the addresses.

Training

We’ll offer training for providers to learn how to access and use the new provider portal to submit prior authorization requests. Watch for more information.


Washtenaw County Community Mental Health joins crisis services program

Washtenaw County Community Mental Health is the newest organization to join Blue Cross Blue Shield of Michigan’s crisis services program. It offers both mobile crisis and residential crisis services.

For mobile crisis services or to determine the location of the appropriate facility for the member, call 734-544-3050.

Our crisis services program was designed to offer our members (and their family members) a wider array of care options if they’re experiencing a mental health crisis.

To learn more about the program and to see a list of other participating facilities, visit the Crisis Care section of our behavioral health website.


Reminder: Signature required on medical records

What you need to know

Medical records require a provider’s signature. This article reviews what constitutes acceptable electronic and handwritten signatures.

  • Electronic signatures must include a name, date, credentials and attestation statement.
  • Handwritten signatures must include a legible signature, including credential. An illegible signature is allowed when provided on letterhead or other information on the page identifies the signer’s identity.

A signature is mandatory on medical records to identify who provided services for the patient. It also validates the services were documented, reviewed and authenticated by the provider.

Requirements for an acceptable signature depend on whether the medical record is generated by an electronic health record or is handwritten.

Services performed by nonphysician practitioners who require physician supervision must be signed by the overseeing provider. Examples of services requiring a supervising physician signature include therapeutic and behavioral health. This includes providers supervising licensed social workers, behavioral health therapists, massage therapists and registered nurses performing administration of drugs.

Electronic signatures

Electronic signatures must be generated by encrypted or password-protected software and used solely by the author of the report or record.

The Medicare Integrity Manual (Ch. 3, 3.3.2.4) states:

“Providers using electronic systems need to recognize that there is a potential for misuse or abuse with alternate signature methods. For example, providers need a system and software products that are protected against modification, etc., and should apply adequate administrative procedures that correspond to recognized standards and laws. The individual whose name is on the alternate signature method and the provider bear the responsibility for the authenticity of the information for which an attestation has been provided. Physicians are encouraged to check with their attorneys and malpractice insurers concerning the use of alternative signature methods.”

Electronic signatures must contain the following key elements:

  • Practitioner’s name
  • Credentials
  • Date
  • Printed attestation statement

Acceptable attestation statements include the following:

  • Accepted by
  • Acknowledged by
  • Approved by
  • Authenticated by
  • Closed by
  • Digitally signed by
  • Electronically authored by
  • Finalized by
  • Generated by
  • Released by
  • Reviewed by
  • Signed by
  • Validated by
  • Performed by (when exam and related documentation are performed by the same provider)

Example (electronic signature and attestation statement):

  • Electronically signed by: Eli Carson, M.D. 09/18/2023
  • Approved by: Peter Wilsby, NP 08/23/2023

Unacceptable electronic signatures include the following:

  • Signature on file
  • Electronically signed by agent of provider
  • Signed but not read
  • Electronically signed, but not authenticated
  • Electronically signed, but not validated or verified

Examples:

  • Electronically signed, but not authenticated George Hudson, M.D.
  • Peter Cunningham, M.D. 07/14/2023
  • Signed Jessica Kastle (No credentials)

Handwritten signatures

Handwritten signatures may only be used on handwritten, transcribed or dictated reports. Handwritten signatures aren’t valid on reports generated from an electronic health records system.
 
A handwritten signature is acceptable if it is:

  • A fully legible signature, including credential
  • A legible first initial, last name and credential
  • An illegible signature, or initials, when over a typed or printed name and credential
  • An illegible signature when the letterhead or other information on the page indicates the identity and credential of the signer

The Medicare Program Integrity Manual (Chapter 3) requires a handwritten signature be legible and include the provider’s credentials. An illegible signature is allowed when the letterhead or other information on the page indicates the identity and credential of the signer.

For additional guidance, refer to the Medicare Program Integrity Manual** and the June 2018 Record article, Medical Record Signatures: What’s acceptable?

**Blue Cross Blue Shield of Michigan doesn’t own or control this website.


Update: Starting Jan. 1, 2024, all DME codes will be removed from the CareCentrix HIT and AIS program

This is an update to previous newsletter articles on this topic that ran in The Record and BCN Provider News. The articles contained three incorrect HCPCS codes. Use the following article as your reference going forward.

For dates of service on or after Jan. 1, 2024, the durable medical equipment codes listed in the table below will be removed from the CareCentrix network management program for home infusion therapy and ambulatory infusion suite providers.

HCPCS codes

B4034

B4035

B4036

B4081

B4082

B4083

B4087

B4102

B4103

B4104

B4105

B4149

B4150

B4152

B4153

B4154

B4155

B4157

B4158

B4159

B4160

B4161

B4162

B4185

B4187

B9002

B9998

 

 

 

This change applies to:

  • Blue Cross Blue Shield of Michigan and Blue Care Network commercial members
  • Independent home infusion therapy and ambulatory infusion suite providers
    Note: Ambulatory infusion suite providers are a subset of ambulatory infusion centers.

These codes are still part of the DME benefit. Providers who participate in Blue Cross’ or BCN’s DME network can bill them in accordance with existing Blue Cross or BCN billing guidelines.

Prior to Jan. 1, 2024, we’ll update the Home infusion therapy and ambulatory infusion suite provider network management: Frequently asked questions document to reflect this change.

CareCentrix is an independent company that manages the in-state, independent home infusion services and ambulatory infusion center provider network for Blue Cross Blue Shield of Michigan and Blue Care Network members who have commercial plans.


Northwood to manage outpatient diabetes supplies for some members, starting Jan. 1

Starting Jan. 1, 2024, Northwood Inc., an independent company, will manage outpatient diabetes supplies that are covered under the medical benefit for members with:

  • Medicare Plus Blue℠
  • Blue Care Network commercial
  • BCN Advantage℠

For these members, Northwood will:

  • Maintain the statewide provider network for durable medical equipment and prosthetic and orthotic supplies and services.
  • Receive and make determinations on prior authorization requests.
  • Process and pay claims for covered services.

Outpatient diabetes supplies include items such as continuous glucose monitors, insulin pumps and supplies, and testing supplies.

Contact Northwood starting Jan. 1

Starting Jan. 1, for diabetes supplies for Medicare Plus Blue, BCN commercial and BCN Advantage members, health care providers can call Northwood's Customer Service department at 1 800-393-6432 to locate the nearest supplier contracted with Northwood. The contracted supplier will:

  • Submit the prior authorization requests to Northwood for review.
  • Submit the claims directly to Northwood.

Providers who currently submit orders directly to J&B Medical may continue to do so. J&B Medical is an independent company that participates in the Northwood network.


Some diabetes drugs to require prior authorization for Blue Cross and BCN members, starting Jan. 1

Beginning Jan. 1, 2024, the presence of prior pharmacy claims for insulin alone will no longer qualify Blue Cross Blue Shield of Michigan commercial and Blue Care Network commercial members for coverage of the medications in the table listed below. We’ll require a prior authorization to confirm that the medications listed below are being used for Type 2 diabetes for members who don’t have a supporting prescription or medical record with a diabetes diagnosis.

The full-coverage requirements are listed in the table below.

Brand-name medication

FDA-approved indication

Coverage requirements starting Jan. 1

Bydureon®
Byetta®
Mounjaro®
Ozempic®

Rybelsus®
Trulicity®
Victoza®

 

 

 

 

 

 

Type 2 diabetes

Coverage without prior authorization will require diagnosis of Type 2 diabetes verified by one of the following:

  • Trial of one generic or preferred medication for the treatment of Type 2 diabetes within the prior 12-month period, except for metformin, GLP-1 receptor agonist, or insulin**
  • Diagnosis code for Type 2 diabetes identified in medical claim history within the prior 24-month period

If either coverage criteria outlined above isn’t fulfilled, you must submit a prior authorization to confirm that your patient has a diagnosis of Type 2 diabetes for coverage.

**Effective Jan. 1, 2024, previous trial of only insulin will no longer qualify members for coverage without prior authorization if they don’t have a medical diagnosis of Type 2 diabetes.

For more information on how to submit an authorization electronically:

  1. Go to ereferrals.bcbsm.com.
  2. Select Blue Cross for PPO members or BCN for HMO members.
  3. Click on Pharmacy Benefit Drugs on the left.
  4. Scroll down to How to submit an electronic prior authorization, or ePA, request

A complete list of included drugs and coverage requirements for all drug lists is available at bcbsm.com/druglists.


Updated COVID-19 vaccines approved by FDA

The U.S. Food and Drug Administration recently amended the emergency use authorization of COVID-19 vaccines from Moderna,** Novavax** and Pfizer-BioNTech** to include the 2023-24 formula.

Use the following procedure codes for COVID-19 monovalent vaccine administration and products: *90480, *91304, *91318, *91319, *91320, *91321 and *91322. 

For more information, see the following:

The vaccine administration and products are part of members’ preventive benefits. For most health plans, there’s no member cost sharing. See below for information about checking vaccine benefits for Blue Cross Blue Shield of Michigan commercial groups that may have cost sharing or may not have vaccine coverage.

Blue Cross commercial groups that may have cost sharing or may not have vaccine coverage

For members who have coverage through Blue Cross commercial groups that are exempt from the Patient Protection and Affordable Care Act, members may have cost sharing or they may not have vaccine coverage.

Here’s how to check member eligibility and benefits for vaccines:

  1. Log in to our provider portal (availity.com).**
  2. Click on Patient Registration in the menu bar and then click on Eligibility and Benefits Inquiry.
  3. Enter the payer information and complete the fields in the Provider Information section.
  4. Complete the Patient Information section and click on Search.
  5. Select the row for the appropriate member.
  6. In the Service Information section, enter Immunizations in the Benefit/Service Type field.
  7. Click on Submit.
  8. Do one of the following:

If…

Then…

There is a Benefit Explainer button near the top of the screen

  1. Click on the Benefit Explainer button.
  2. Tip: If Benefit Explainer doesn’t open, you’ll need to allow Availity® Essentials to open popups.

  3. In Benefit Explainer, click on the Search button.
  4. Press CTRL+F.
  5. Search Preventive Immunizations.

There isn’t a Benefit Explainer button near the top of the screen

  1. Press CTRL+F.
  2. Search on Immunizations.

For more information on our vaccines, see the article “Blue Cross and BCN covering additional vaccines,” also in this issue.

None of the information included in this article is intended to be legal advice and, as such, it remains the provider’s responsibility to ensure that all coding and documentation are done in accordance with all applicable state and federal laws and regulations.

Availity® is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to offer provider portal and electronic data interchange services.

**Blue Cross Blue Shield of Michigan doesn’t own or control this website.


Requirements and codes changed for some medical benefit drugs

As part of our efforts to encourage appropriate use of high-cost medications covered under the medical benefit, we recently added requirements for some medical benefit drugs. Also, the Centers for Medicare & Medicaid Services assigned some drugs new HCPCS codes. The changes went into effect on various dates in July, August and September.

Changes in requirements

For Blue Cross Blue Shield of Michigan commercial and Blue Care Network commercial members, we added prior authorization requirements for the following:

HCPCS code

Brand name

Generic name

J3590**

Elevidys

Delandistrogene moxeparvovec-rokl

J3590**

Eylea® HD

Aflibercept

J3590**

Izervay™

Avacincaptad pegol

J3590**

Lantidra™

Donislecel-jujn

J3590**

Roctavian™

Waloctocogene roxaparvovec-rvox

J3590**

Rystiggo®

(Rozanolixizumab-noli)

J3590**

Tyruko®

Natalizumab-sztn

J3590**

Veopoz™

Pozelimab-bbfg

J3590**

Vyvgart® Hytrulo

(Efgartigimod alfa and hyaluronidase-qvfc)

For Medicare Plus Blue℠ and BCN Advantage℠ members, we added prior authorization requirements for the following:

HCPCS code

Brand name

Generic name

For dates of service on or after

J3590**

Elevidys

Delandistrogene moxeparvovec-rokl

July 10, 2023

J3590**

Roctavian™

Valoctocogene roxaparvovec-rvox

July 10, 2023

J3590**

Rystiggo®

Rozanolixizumab-noli

July 10, 2023

J3490**

Vyvgart® Hytrulo

Efgartigimod alfa and hyaluronidase-qvfc

July 10, 2023

J3590**

Qalsody™

Tofersen

Aug. 1, 2023

J3590**

Elfabrio®

Pegunigalsidase alfa-iwxj

Aug. 14, 2023

J3590**

Vyjuvek™

Beremagene geperpavec-svdt

Aug. 14, 2023

J3590**

Veopoz™

Pozelimab-bbfg

Sept. 1, 2023

Code changes

The table below shows HCPCS code changes that were effective July 1, 2023, (unless otherwise noted) for medical benefit drugs we manage.

New HCPCS code

Brand name

Generic name

J1440

Rebyota™

Fecal microbiota, live-jslm

J1576

Panzyga®

Immune globulin Intravenous (human) – ifas 10%

J9381

Tzield®

Teplizumab-mzwv

J9029

Adstiladrin®

Nadofaragene firadenovec-vncg

J0174 (effective July 6, 2023)

Leqembi®

Lecanemab-irmb

Drug lists

For additional details, see the following drug lists:

These lists are also available on the following pages of the ereferrals.bcbsm.com website:

More information about these requirements

We communicated these changes previously through provider alerts. Those alerts contain additional details.

You can view the provider alerts on ereferrals.bcbsm.com and on our Provider Resources site, which is accessible through our provider portal (availity.com).***

More information for Blue Cross commercial groups

For Blue Cross commercial groups, authorization requirements apply only to groups that participate in the standard commercial Medical Drug Prior Authorization Program for drugs administered under the medical benefit. To determine whether a group participates in the prior authorization program, see the Specialty Pharmacy Prior Authorization Master Opt-in/out Group list. A link to this list is also available on the Blue Cross Medical Benefit Drugs page of the ereferrals.bcbsm.com website.

Note: Blue Cross and Blue Shield Federal Employee Program® members and UAW Retiree Medical Benefits Trust (non-Medicare) members don't participate in the standard prior authorization program

Reminder

An authorization approval isn’t a guarantee of payment. As always, health care providers need to verify eligibility and benefits for members.

Availity® is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to offer provider portal and electronic data interchange services.

**May be assigned a unique code in the future.

***Blue Cross Blue Shield of Michigan and Blue Care Network doesn’t own or control this website.

***Blue Cross Blue Shield of Michigan and Blue Care Network doesn’t own or control this website.


Starting Jan. 1, we’ll change how we cover some drugs on Clinical, Custom, Custom Select and Preferred drug lists

Our goal at Blue Cross Blue Shield of Michigan and Blue Care Network is to provide our members with safe, high-quality prescription drug therapies. We continually review prescription drugs so we can provide the best value for our members, control costs and make sure our members are using the right drugs for the right situations.

Starting Jan. 1, 2024, we’ll change how we cover some medications on the Clinical, Custom, Custom Select and Preferred drug lists. We’ll send letters to notify affected members, their groups and their health care providers about these changes.

Drugs that won’t be covered on the Clinical, Custom and Custom Select Drug lists
We’ll no longer cover the drugs listed in the table below. Unless noted, both the brand name and available generic equivalents won’t be covered. If a member fills a prescription for one of these drugs on or after Jan. 1, 2024, they’ll be responsible for the full cost.

The drugs that won’t be covered are listed along with suggested covered preferred alternatives that have similar effectiveness, quality and safety. When pharmacies fill prescriptions with preferred alternatives, the generic equivalents are dispensed, if available. Additional coverage requirements may apply for preferred alternatives, such as prior authorization.

Drugs that won’t be covered

Affected drug lists

Common use or drug class

Preferred alternatives

Generic doxycycline monohydrate 75mg capsule

Custom Select

Tetracycline antibiotic

  • Generic doxycycline hyclate capsule; 100mg tablet
  • Generic doxycycline monohydrate 50mg, 100mg capsule; 50mg, 75mg, 100mg tablet

APO-varenicline

Clinical, Custom, Custom Select

Smoking cessation

Generic varenicline tartrate (Chantix®)

Copaxone® 20mg/mL
(brand glatiramer)

Custom Select

Multiple sclerosis

Generic glatiramer 20mg/mL, 40mg/mL (Glatopa®)

Drugs that will have a higher copayment on Clinical, Custom and Custom Select drug lists

The brand-name drugs that will have a higher copayment are listed in the table below along with suggested covered preferred alternatives that have similar effectiveness, quality and safety. When pharmacies fill prescriptions with preferred alternatives, the generic equivalents are dispensed, if available. Additional coverage requirements may apply for preferred alternatives.

Drugs that will have a higher copayment**

Affected drug lists

Common use or 
drug class

Preferred alternatives

Generic doxycycline monohydrate 75mg capsule

Custom
(HMO only)

Tetracycline antibiotic

  • Generic doxycycline hyclate capsule; 100mg tablet
  • Generic doxycycline monohydrate 50mg, 100mg capsule; 50mg, 75mg, 100mg tablet

Generic doxycycline monohydrate 150mg tablet

Custom
(HMO only)
Custom Select (HMO only)

Copaxone® 20mg/mL
(brand glatiramer)

Clinical, Custom

Multiple sclerosis

Generic glatiramer 20mg/mL, 40mg/mL (Glatopa®)

**Nonpreferred brand drugs aren’t covered for members with a closed benefit.

Brand-name drugs no longer covered with generic copay on HMO Custom Drug List

On some of our drug lists, select brand-name drugs are covered at a generic copay and the generic equivalent drug isn’t covered. These brand-name drugs will no longer be covered at the generic copay. Members can fill prescriptions with the generic equivalent.

Brand-name drug

Affected drug lists

Covered generic equivalent

Adderall® XR

Custom
(HMO only)

Dextroamphetamine/ amphetamine ER capsule

Drugs that won’t be covered on the Preferred Drug List

We’ll no longer cover the drugs in the table below. Unless noted, both the brand name and available generic equivalents won’t be covered. If a member fills a prescription for one of these drugs on or after Jan.1, 2024, they’ll be responsible for the full cost.

The drugs that won’t be covered are listed in the table below along with suggested covered preferred alternatives that have similar effectiveness, quality and safety. When pharmacies fill prescriptions with preferred alternatives, the generic equivalents are dispensed, if available. Additional coverage requirements may apply for preferred alternatives, such as prior authorization.

Drugs that won’t be covered

Common use or drug class

Preferred alternatives

Adhansia XR®

Attention-deficit/hyperactivity disorder (ADHD)

  • Generic methylphenidate (such as Ritalin® LA, Concerta®)
  • Generic dexmethylphenidate (such as Focalin® XR)
  • Generic amphetamine/ dextroamphetamine (such as Adderall® XR)
  • Lisdexamphetamine (Vyvanse®)

Aklief®, Arazlo®

Acne vulgaris

  • Generic adapalene 0.1% cream, gel (Differin®)
  • Generic adapalene-benzoyl peroxide gel 0.1-2.5% (Epiduo®)
  • Generic tazarotene 0.1% cream, gel (Tazorac®)

Aplenzin®, Forfivo XL®, bupropion ER 450mg (authorized brand alternative for Forfivo XL®)

Depression

Generic bupropion ER (Wellbutrin® SR/XL)

APO-varenicline

Smoking cessation

Generic varenicline tartrate (Chantix®)

Copaxone® 20mg/mL (brand glatiramer)

Multiple sclerosis

Generic glatiramer 20mg/mL, 40mg/mL (Glatopa®)

Generic dapsone 7.5% gel (Aczone®)

Acne vulgaris

Generic dapsone 5% gel (Aczone®)

Evekeo ODT®

Attention-deficit/hyperactivity disorder – ADHD

  • Generic dextroamphetamine solution (ProCentra®)
  • Generic methylphenidate solution, chewable tablet (Methylin®)

FloLipid®

Hypercholesterolemia

  • Generic statin (such as rosuvastatin (Crestor®)
  • Fluvastatin (Lescol XL®)
  • Atorvastatin (Lipitor®)
  • Pravastatin (Pravachol®)
  • Simvastatin (Zocor®)

Impoyz®

High-potency topical steroid

Generic high-potency topical steroid (such as betamethasone 0.5% cream, lotion; desoximetasone 0.25% cream, diflorasone 0.5% cream, flucinonide 0.5% cream, lotion; halcinonide 0.1% cream)

Lexette®, Ultravate® 0.05% lotion

Ultra-high-potency topical steroid

Generic ultra-high-potency topical steroid (such as clobetasol 0.05% cream, foam, spray; flucinonide 0.1% cream, halobetasol 0.05% cream, lotion)

Kristalose® packet

Constipation

Generic lactulose oral solution

Generic meclizine 50mg tablet

Vertigo, motion sickness

Generic meclizine 12.5mg, 25mg tablet

Ortikos®

Crohn’s disease

Generic budesonide 3mg capsule

Osmolex ER®

Parkinson’s disease

Generic amantadine tablet, solution

Oxaydo®

Pain

Generic oxycodone tablet

Phenergan Fortis® 25mg/5mL syrup

Nausea and vomiting

Generic promethazine 6.25mg/5mL syrup

Roszet®

Hypercholesterolemia

Generic ezetimibe (Zetia®) plus generic rosuvastatin (Crestor®)

Sernivo®

Moderate-potency topical steroid

Generic moderate-potency topical steroid (such as betamethasone 0.12% foam, desoximetasone 0.05% cream, fluticasone 0.05% cream, lotion; mometasone 0.1% cream, lotion; triamcinolone 0.2% spray)

Sprix®

Pain

Generic ketorolac tablet, injection

Generic tavaborole (Kerydin®)

Onychomycosis (nail fungus)

Ciclodan topical solution

Teriparatide 620 mcg/2.48mL injection

Osteoporosis

Forteo®, Tymlos®

Tosymra®

Migraine

  • Generic triptan (such as sumatriptan nasal spray (Imitrex®)
  • Zolmitriptan 5mg nasal spray (Zomig®)
  • Orally disintegrating tablet (Zomig ZMT®)
  • Rizatriptan orally-disintegrating tablet (Maxalt-ODT®)

Wynzora®

Plaque psoriasis

  • Generic calcipotriene/betamethasone ointment (Taclonex®)
  • Generic tazarotene 0.1% cream (Tazorac®)
  • Enstilar®

Xerese®

Herpes labialis (cold sores)

Generic acyclovir 5% ointment

Zilxi®

Rosacea

  • Generic azelaic 15% gel (Finacea®)
  • Generic metronidazole 0.75% cream, lotion (MetroCream®, MetroLotion®)
  • Finacea® foam

Drugs that will have a higher copayment on the Preferred Drug List

The brand-name drugs that will have a higher copayment are listed along with suggested covered preferred alternatives that have similar effectiveness, quality and safety. When pharmacies fill prescriptions with preferred alternatives, the generic equivalents are dispensed, if available. Additional coverage requirements may apply for preferred alternatives.

Drugs that will have a higher copayment

Common use or 
drug class

Preferred alternatives

Nulev®

Gastrointestinal conditions

Generic hyoscyamine sulfate 0.125mg, 0.375mg tablet (Such as Levsin®, Levbid®)

Sucraid®

Congenital sucrase-isomaltase deficiency

Discuss treatment options with your provider.

Xywav®

Narcolepsy, Idiopathic hypersomnia

Discuss treatment options with your provider.

Zomig® 2.5mg nasal spray

Migraine

  • Generic triptan (such as sumatriptan nasal spray (Imitrex®)
  • Zolmitriptan 5mg nasal spray (Zomig®)
  • Orally disintegrating tablet (Zomig ZMT®)
  • Rizatriptan orally disintegrating tablet (Maxalt-ODT®)

Brand-name drugs with a generic copay that won’t be covered on the Preferred Drug List

On some of our drug lists, select brand-name drugs are covered at a generic copay and the generic equivalent drug isn’t covered. These brand-name drugs will no longer be covered at the generic copay. Members can fill prescriptions with the generic equivalent, and the brand-name drug will no longer be covered.

Brand-name drug

Covered generic equivalent

Adderall® XR

Dextroamphetamine/ amphetamine ER capsule

Advair® Diskus®

Fluticasone propionate/salmeterol Diskus, Wixela® Inhub®

Firazyr®

Icatibant acetate injection

Lialda®

Mesalamine 1.2 g tablet

Targretin® capsule

Bexarotene capsule

Targretin® gel

Bexarotene gel


Changes coming to preferred drug designations under medical benefit for most commercial members

For dates of service on or after Jan. 1, 2024, Blue Cross Blue Shield of Michigan and Blue Care Network are making changes to preferred drug designations for some products. In addition, providers will need to submit prior authorization requests through different systems for some preferred and nonpreferred drugs.

These changes will affect:

  • Most Blue Cross commercial members
    • Exception: These changes don’t apply to UAW Retiree Medical Benefits Trust non-Medicare members or Blue Cross and Blue Shield Federal Employee Program® members.
  • All BCN commercial members

Changes to preferred drug designations

We’re changing preferred drug designations as shown in the following table. Changes are in bold text.

Product

Preferred drugs

Before Jan. 1, 2024

On or after Jan. 1, 2024

Bevacizumab

  • Mvasi®
  • Zirabev®

Mvasi only

Pegfilgrastim

  • Fulphila
  • Neulasta®, Neulasta® OnPro®
  • Ziextenzo®
  • Neulasta, Neulasta OnPro
  • Nyvepria®

Rituximab

  • Riabni™
  • Ruxience®
  • Ruxience
  • Truxima®

Trastuzumab

  • Kanjinti®
  • Trazimera®
  • Kanjinti
  • Ogivri®

How existing prior authorizations are affected by these changes

Existing prior authorizations are affected as follows:

  • For bevacizumab, rituximab and trastuzumab products, the member can continue taking a drug that will be designated as nonpreferred after Jan. 1 until their existing authorization expires. However, we encourage health care providers to begin using products that will be designated as preferred starting Jan. 1, 2024.
  • For pegfilgrastim products, active authorizations for Fulphila and Ziextenzo will end Dec. 31, 2023. Providers will need to transition members who are currently taking Fulphila or Ziextenzo to a preferred drug for dates of service on or after Jan. 1, 2024.

Changes to prior authorization processes

The following table outlines prior authorization requirements for the drugs listed above for dates of service on or after Jan. 1, 2024.

To determine which Blue Cross commercial groups have opted in to the Carelon medical oncology program, see the Carelon medical oncology prior authorization program opt-in list for Blue Cross commercial self-funded groups.

Lines of business

Changes to requirements

  • BCN commercial members
  • Blue Cross commercial members whose groups participate in the Carelon medical oncology program
  • Preferred drugs will require prior authorization through Carelon Medical Benefits Management.
  • Exception: Rituximab preferred drugs won’t require prior authorization.

  • Nonpreferred drugs will require prior authorization through NovoLogix. 

Blue Cross commercial members whose groups don’t participate in the Carelon medical oncology program

  • Preferred products won’t require prior authorization.
  • Nonpreferred products will require prior authorization through NovoLogix.  

Additional information

For additional information on requirements related to drugs covered under the medical benefit, refer to the following drug lists:

For additional information about medical benefit drugs, see the following pages of our ereferrals.bcbsm.com website:


Lumoxiti no longer requires prior authorization

Lumoxiti™ (moxetumomab pasudotox-tdfk), HCPCS code J9313, no longer requires prior authorization through Carelon Medical Benefits Management (formerly known as AIM Specialty Health®). This change applies to the following members for dates of service on or after Sept. 30, 2023:

  • Blue Cross Blue Shield of Michigan commercial
  • Medicare Plus Blue℠ members
  • Blue Care Network commercial members
  • BCN Advantage℠ members

This drug is covered under members’ medical benefits, not their pharmacy benefits.

More about prior authorization requirements

For information on requirements related to drugs covered under the medical benefit, refer to the following drug lists:

Carelon Medical Benefits Management is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to manage prior authorizations for select services.


Beyfortus to have quantity limits for commercial members, starting Jan. 1

Starting Jan. 1, 2024, Beyfortus™ (nirsevimab-alip), procedure codes *90380 and *90381, will have quantity limits when billed under the pharmacy benefit. There won’t be quantity limits when Beyfortus is billed under the medical benefit.

Note: For the administration of Beyfortus, use procedure codes *96380 and *96381.

Administration site and coverage details

Beyfortus is covered as follows.

Administration site

How it’s covered

Health care provider’s office

Under the medical benefit, with no quantity limits

Retail pharmacy when the member has pharmacy benefits through Blue Cross Blue Shield of Michigan or Blue Care Network

Under the pharmacy benefit

Quantity limits will apply

Retail pharmacy when both of the following are true:

  • The member doesn’t have pharmacy benefits through Blue Cross or BCN.
  • The pharmacy participates in the Blue Cross Vaccine Affiliation Program.

Under the medical benefit, with no quantity limits


Blue Cross commercial groups that may have cost sharing or may not have vaccine coverage

For members who have coverage through Blue Cross Blue Shield of Michigan commercial groups that are exempt from the Patient Protection and Affordable Care Act, members may have cost sharing or they may not have vaccine coverage.

Here’s how to check member eligibility and benefits for vaccines:

  1. Log in to our provider portal (availity.com).**
  2. Click on Patient Registration in the menu bar and then click on Eligibility and Benefits Inquiry.
  3. Enter the payer information and complete the fields in the Provider Information section.
  4. Complete the Patient Information section and click on Search.
  5. Select the row for the appropriate member.
  6. In the Service Information section, enter Immunizations in the Benefit/Service Type field.
  7. Click on Submit.
  8. Do one of the following:

If…

Then…

There is a Benefit Explainer button near the top of the screen

  1. Click on the Benefit Explainer button.
  2. Tip: If Benefit Explainer doesn’t open, you’ll need to allow
    Availity® Essentials to open popups.
  3. In Benefit Explainer, click on the Search button.
  4. Press CTRL+F.
  5. Search on Preventive Immunizations.

There isn’t a Benefit Explainer button near the top of the screen

  1. Press CTRL+F.
  2. Search on Immunizations.

None of the information included in this article is intended to be legal advice and, as such, it remains the provider’s responsibility to ensure that all coding and documentation are done in accordance with all applicable state and federal laws and regulations.

Availity® is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to offer provider portal and electronic data interchange services.

**Blue Cross Blue Shield of Michigan and Blue Care Network don’t own or control this website.


Zynyz to require prior authorization for most members, starting Dec. 10

For dates of service on or after Dec. 10, 2023, Zynyz™ (retifanlimab-dlwr), HCPCS code J9345, will require prior authorization through Carelon Medical Benefits Management (formerly known as AIM Specialty Health®).

The drug is covered under the members’ medical benefits, not their pharmacy benefits.

Prior authorization requirements apply when the drug is administered in outpatient settings for:

  • Blue Cross Blue Shield of Michigan commercial
    • All fully insured members (group and individual)
    • Members who have coverage through self-funded groups that have opted in to the Carelon medical oncology program. (Although UAW Retiree Medical Benefits Trust non-Medicare plans have opted in to this program, these requirements may not apply; refer to their medical oncology drug list, which is linked below.)
      Note: This requirement doesn’t apply to members who have coverage through the Blue Cross and Blue Shield Federal Employee Program®.
  • Medicare Plus Blue℠ members
  • Blue Care Network commercial members
  • BCN Advantage℠ members

How to submit authorization requests

Submit authorization requests to Carelon using one of the following methods:

  • Through the Carelon ProviderPortal, which you can access by doing one of the following:
    • Logging in to our provider portal (availity.com),** clicking on Payer Spaces and then clicking on the BCBSM and BCN logo. This takes you to the Blue Cross and BCN payer space where you’ll click on the Carelon ProviderPortal tile.
      Note: If you need to request access to our provider portal, see the Register for web tools webpage on bcbsm.com.
  • By calling the Carelon Contact Center at 1-844-377-1278

More about the prior authorization requirements

For additional information on requirements related to drugs covered under the medical benefit, refer to the following drug lists:

We’ll update the pertinent drug lists to reflect the information in this message prior to the effective date.
As a reminder, authorization isn’t a guarantee of payment. Health care practitioners need to verify eligibility and benefits for members.

Carelon Medical Benefits Management is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to manage prior authorizations for select services.

Availity® is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to offer provider portal and electronic data interchange services.

**Blue Cross Blue Shield of Michigan doesn’t own or control this website.


Facilities must submit appeals within required time frames

What you need to know

  • We reinstated the time frames for submitting appeals for nonapproved prior authorization requests on July 1, after waiving those time frames during the COVID-19 public health emergency.
  • The time frames for Level One and Level Two appeals are highlighted in the chart below.
  • You can find more information in our provider manuals.

Facilities must submit appeals of nonapproved inpatient medical and surgical (non-behavioral health) prior authorization requests within the time frames stated in the denial letters. 

We reinstated the usual appeals time frames on July 1

During the COVID-19 public health emergency, Blue Cross Blue Shield of Michigan and Blue Care Network waived the time frames for submitting appeals. We reinstated the time frames for submitting appeals, starting July 1, 2023. This was communicated in a May 1, 2023, provider alert.

Time frames for submitting appeals

Here are the time frames for submitting appeals of inpatient medical and surgical (non‑behavioral health) prior authorization requests that we’ve denied:

  • For initial denial decisions made before July 1, 2023, we’ll stop accepting appeals on Jan. 1, 2024.
  • For initial denial decisions made on or after July 1, 2023, the usual time frames for appeals apply; see the table below.

Plan

How it works

Blue Cross commercial

  • A Level One appeal must be submitted within 45 days of the date on the original denial letter. Appeals submitted after the 45th day won’t be accepted.
  • A Level Two appeal must be submitted within 20 days of the date on the Level One appeal denial letter. Appeals submitted after the 20th day won’t be accepted.

Medicare Plus Blue℠
BCN commercial
BCN Advantage℠

  • A Level One appeal must be submitted within 45 days of the date on the original denial letter.
  • A Level Two appeal must be submitted within 21 days of the date on the Level One appeal denial letter.
  • If a Level One appeal is submitted after the 45th day but by the 66th day, it will be processed as a Level Two appeal.
  • Appeals received more than 66 days after the date on the original denial letter won’t be accepted.

Where to find additional information

For additional information about submitting appeals of prior authorization requests that aren’t approved, refer to the pertinent provider manual:

  • Blue Cross commercial: Refer to the “Preapproval of Services” chapter. Look in the section titled “Appealing a prior authorization decision.” 
  • Medicare Plus Blue: In the Medicare Plus Blue PPO Provider Manual, look in the section titled “Appealing Medicare Plus Blue’s Decision.”  
  • BCN commercial and BCN Advantage: Refer to these two chapters in the BCN Provider Manual:

To access the provider manuals:

  1. Log in to our provider portal (availity.com).**
  2. Click on Payer Spaces on the menu bar and then click the BCBSM and BCN logo.
  3. Click on the Resources tab.
  4. Click on Provider Manuals.

Availity® is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to offer provider portal and electronic data interchange services.

**Blue Cross Blue Shield of Michigan and Blue Care Network don’t own or control this website.


Update: TurningPoint medical policies for musculoskeletal and pain management procedures

In an article in the September Record and the September-October BCN Provider News, we reported that Blue Cross Blue Shield of Michigan, Blue Care Network and TurningPoint Healthcare Solutions LLC added and updated TurningPoint medical policies for musculoskeletal and pain management procedures.

The newsletter articles linked to a provider alert for details. We’re letting you know that we updated the provider alert to:

  • Add the Intraosseous Basivertebral Nerve Ablation (Intracept) medical policy to the list of new TurningPoint medical policies.
  • Explain that the new and updated medical policies apply to prior authorization requests submitted on or after Oct. 1, 2023 — not to dates of service on or after Oct. 1, as previously reported.

View the updated provider alert for full details.

TurningPoint Healthcare Solutions LLC is an independent company that manages authorizations for musculoskeletal surgical and related procedures for Blue Cross Blue Shield of Michigan and Blue Care Network.


Reminder: Independent labs must provide advance notice to Blue Cross commercial members before providing noncovered services

Here’s information you need to know about providing noncovered services to Blue Cross Blue Shield of Michigan commercial members at outpatient laboratories.

Independent laboratories

Before receiving noncovered services at independent laboratories, Blue Cross commercial members must sign the Advance Notice of Member Responsibility form.

Prior to having members sign the form, be sure to familiarize yourself with the requirements under our Clinical Laboratory Agreement.

The language in this agreement states that independent laboratories may bill members for services that Blue Cross has deemed to be not medically necessary only when all of the following are true:

  • Each member must specifically agree to these conditions in advance:
    • The member acknowledges that Blue Cross won’t pay for specific services because they were deemed medically unnecessary.
    • The member consents to receiving the services before the services are provided.
    • The member assumes financial responsibility for the services.
    • The health care provider provides the member with an estimated cost for the services.
  • Each form must state that Blue Cross won’t pay for the specific services and must include a price estimate for each service.

To access the Advance Notice of Member Responsibility form: 

  1. Log in to our provider portal (availity.com).**
  2. Click on Payer Spaces in the menu, then click on the BCBSM and BCN logo.
  3. Click on the Resources tab.
  4. Click on the Secure Provider Resources (Blue Cross and BCN) link.
  5. On the Provider Resources site, click on Forms in the menu, then on click Prior Authorization.
  6. Click on the Advance Notice of Member Responsibility for GY or GZ modifiers (PDF) link.

Hospital laboratories

The Advance Notice of Member Responsibility form isn’t approved for use by hospital labs at this time. We’re currently reviewing the processes for hospital labs. Watch for an upcoming provider alert and Record article with more information.

Availity® is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to offer provider portal and electronic data interchange services.

**Blue Cross Blue Shield of Michigan doesn’t own or control this website.

DME

Update: Starting Jan. 1, 2024, all DME codes will be removed from the CareCentrix HIT and AIS program

This is an update to previous newsletter articles on this topic that ran in The Record and BCN Provider News. The articles contained three incorrect HCPCS codes. Use the following article as your reference going forward.

For dates of service on or after Jan. 1, 2024, the durable medical equipment codes listed in the table below will be removed from the CareCentrix network management program for home infusion therapy and ambulatory infusion suite providers.

HCPCS codes

B4034

B4035

B4036

B4081

B4082

B4083

B4087

B4102

B4103

B4104

B4105

B4149

B4150

B4152

B4153

B4154

B4155

B4157

B4158

B4159

B4160

B4161

B4162

B4185

B4187

B9002

B9998

 

 

 

This change applies to:

  • Blue Cross Blue Shield of Michigan and Blue Care Network commercial members
  • Independent home infusion therapy and ambulatory infusion suite providers
    Note: Ambulatory infusion suite providers are a subset of ambulatory infusion centers.

These codes are still part of the DME benefit. Providers who participate in Blue Cross’ or BCN’s DME network can bill them in accordance with existing Blue Cross or BCN billing guidelines.

Prior to Jan. 1, 2024, we’ll update the Home infusion therapy and ambulatory infusion suite provider network management: Frequently asked questions document to reflect this change.

CareCentrix is an independent company that manages the in-state, independent home infusion services and ambulatory infusion center provider network for Blue Cross Blue Shield of Michigan and Blue Care Network members who have commercial plans.


Northwood to manage outpatient diabetes supplies for some members, starting Jan. 1

Starting Jan. 1, 2024, Northwood Inc., an independent company, will manage outpatient diabetes supplies that are covered under the medical benefit for members with:

  • Medicare Plus Blue℠
  • Blue Care Network commercial
  • BCN Advantage℠

For these members, Northwood will:

  • Maintain the statewide provider network for durable medical equipment and prosthetic and orthotic supplies and services.
  • Receive and make determinations on prior authorization requests.
  • Process and pay claims for covered services.

Outpatient diabetes supplies include items such as continuous glucose monitors, insulin pumps and supplies, and testing supplies.

Contact Northwood starting Jan. 1

Starting Jan. 1, for diabetes supplies for Medicare Plus Blue, BCN commercial and BCN Advantage members, health care providers can call Northwood's Customer Service department at 1 800-393-6432 to locate the nearest supplier contracted with Northwood. The contracted supplier will:

  • Submit the prior authorization requests to Northwood for review.
  • Submit the claims directly to Northwood.

Providers who currently submit orders directly to J&B Medical may continue to do so. J&B Medical is an independent company that participates in the Northwood network.

No portion of this publication may be copied without the express written permission of Blue Cross Blue Shield of Michigan, except that BCBSM participating health care providers may make copies for their personal use. In no event may any portion of this publication be copied or reprinted and used for commercial purposes by any party other than BCBSM.

*CPT codes, descriptions and two-digit numeric modifiers only are copyright 2022 American Medical Association. All rights reserved.